WO2008034912A2

WO2008034912A2 - Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof

Info

Publication number: WO2008034912A2
Application number: PCT/EP2007/060127
Authority: WO
Inventors: Igor Simonic; Primoz Benkic; Rok Zupet; Matej Smrkolj; Mitja Stukelj
Original assignee: Krka, Tovarna Zdravil, D.D., Novo Mesto
Priority date: 2006-09-22
Filing date: 2007-09-24
Publication date: 2008-03-27
Also published as: EP2078025B1; ZA200902575B; NO20091334L; PL2078025T3; HUE029319T2; WO2008034912A3; SI2078025T1; HRP20160809T1; EP2078025A2; ES2577294T3; SI22383A

Abstract

The present invention relates to a new process for the preparation of clopidogrel and to new polymorphic forms of clopidogrel salts, to processes for their preparation and to a pharmaceutical formulation containing the new forms.

Description

Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof

Technical field

The present invention belongs to the field of organic chemistry and relates to a new process for the synthesis of clopidogrel and pharmaceutically acceptable salts thereof as well as new forms of specific salts thereof and processes for their preparations .

Clopidogrel - preferably its pharmaceutically acceptable salts - is used for inhibiting platelet aggregation or decreasing the frequence of atherosclerotic events (brain strokes or cardiac attacks, mortality due to blood vessel disease) in patients with a symptomatic form of atherosclerotic disease such as recovered brain stroke, myocardial infarct and peripheral arterial occlusive disease.

Technical problem

There exists a need for a new economical process for the synthesis of clopidogrel and of new stable forms of pharmaceutically acceptable salts thereof, which may be used in the preparation of pharmaceutical formulations. There exists also a need for an active ingredient having appropriate properties, such as flowability, particle size, particle distribution, since these properties affect the processability, content, stability and quality of the pharmaceutical formulations .

Prior art

Clopidogrel, having the chemical name (S) - (+) - (2-chlorophenyl) - 6, 7-dihydro-4H-thieno [3, 2-c] pyridm-5-yl acetic acid methyl ester, is described in US 4,847,265. WO 99/65915 discloses polymorphs I and II of clopidogrel hydrogen sulfate, WO 03/51362 discloses polymorphs III, IV, V and VI and an amorphous form as well as a process for the preparation of polymorphs I and II.

The amorphous clopidogrel hydrogen sulfate and its preparation are described in WO 00/010534, WO 04/26879, WO 04/81015, WO 04/81016, WO 04/98593 and WO 05/16931.

WO 03/66637 discloses polymorphs I and II of clopidogrel hydrochloride and WO 05/117866 discloses an amorphous form of clopidogrel hydrochloride. WO 07/029095 discloses polymorph form III of clopidogrel hydrochloride. WO 07/029080, discloses preparation of form I of clopidogrel hydrochloride from various ethers.

The crystallization of polymorphs of clopidogrel salts is an object of numerous patent applications disclosing also the synthesis of clopidogrel: WO 04/20443, WO 04/48385, WO 04/52966, WO 04/106344, WO 05/012300, WO 05/16931, WO 05/26174, WO 05/63708, WO 05/68471, WO 05/80890, WO 05/97804, WO 05/100364, WO 05/103059, WO 05/104663, WO 06/23676, WO 06/34451, WO 06/87226 and WO 06/87729.

Formulations of clopidogrel and its salts as well as processes for its preparation are described in WO 04/74215, WO 04/72085,

WO 04/72084, WO 05/48992, WO 05/70464, WO 06/44548, WO 06/74066, WO 06/91847.

Processes for purification with camphor sulfonic acid and various manners of synthesis are also described in EP 99802, EP 281459, EP 420706, EP 465358, EP 466659, EP 499544, WO 98/51689, WO 98/51682, WO 98/51681, WO 99/65915, WO 99/18110, WO 02/18357, WO 02/59128, WO 03/4502, WO 03/93276, WO 04/74215, WO 04/13147, WO 04/108665, WO 05/77958, WO 05/12300, WO 05/77958, WO 05/8779, WO 05/113559, WO 06/86921, WO 06/94468, US 200559696, CN 1775782 and IP.com Journal (2006) 6 (5A) 5 (No. IPCOM000135479D) , 18 April 2006. Description of the invention

An object of the present invention is a new process for the preparation of clopidogrel of formula I as disclosed in Scheme 1 below:

catalyst.

racemic orpureor opt enriched (+)- form (IV)

cyclization

N-alkylahon racemic or (+)- cπn (IX) -σ>

racemic orpure or cpt enriched (+) form (III) opt resolution

1 N-alkylation

2 cyclization

S cheme 1 The invention also relates to the use of any one of the above reaction steps or any combination of these steps for the preparation of clopidogrel.

A preferred process according to the invention for the preparation of clopidogrel of formula I comprises:

a) converting compound II, (+) - (2-chlorophenyl) ( 6, 7-dihydro-4H- thieno [3, 2-c] pyrid-5-yl) acetic acid, into clopidogrel of formula I according to any one of the processes selected from i) alkylation with alkyl halogenides or alkyl sulfates, ii) esterification with methanol in the presence of acids, in) esterification with mixed anhydrides, iv) esterification via acid halides, and b) optionally converting the clopidogrel rnto a pharmaceutically acceptable salt.

In a preferred embodiment of this process, the compound of formula II is prepared from compound IV, racemic or optically pure or partrally enrrched (+) -N- (2- (2-thienyl) ethyl) -2- chlorophenylglycm, via compound III, racemic or optrcally pure or partially enriched (+ )- (2-chlorophenyl) ( 6, 7-dihydro-4H- thieno [3, 2-c] pyrid-5-yl) acetic acid, wherein the optical resolution can be performed in any step. The optical resolution is preferably performed with optically pure (+)- or (-)camphor- 10-sulfonic acid ( (+) -CSA or (-) -CSA) .

In a further preferred embodiment of the process according to the invention, the compound of formula II is prepared by the reaction of the compound of formula XIII, an optically pure dextro-rotary form of 2-chlorophenylglycin, and the compound of formula VI, 2- (2-thienyl) ethyl benzene sulfonate.

In a further embodiment, the compound of formula II can be prepared via racemic compound of formula IV by optical resolution followed by cyclization. Optical resolution can be performed with optical pure reagents such as for example D- threo-2-amino-l- (4-nitrophenyl) -1, 3-propanediol, (+) -CSA or (-) - CSA. Intermediates II and III can be prepared and further processed according to the processes known m the art such as WO 06/137628 and US 2005/0059696.

The compound of formula IV, (±) -N- (2- (2-thienyl) ethyl) -2- chlorophenylglycin, can be prepared in several possible manners, wherein as the starting compound racemic 2-chlorophenylglycin or an alkyl ester of racemic 2-chlorophenylglycin or oc- (2- chlorophenyl) -α-keto-acetic acid is used. The compound of formula IV can also be prepared by N-alkylation of 2-bromo-2- (2- chlorophenyl) acetic acid with 2- (2-thienyl) ethylamine .

Intermediate IV in form of racemate or optically pure or enriched form can be prepared and purified and further processed according to the processes known in the art such as EP 466569, WO 04/108665, WO 06/3671, WO 07/32023 and WO 07/94006.

Starting compounds IX can be prepared according to the processes known m the art such as EP 402706 wherern bromation of 2- chlorophenyl acetic acid is described. Various bromation agents can be used such as bromine and N-bromosuccinimide (NBS) in various organic solvents such as ethers such as for example diisopropylether, THF, dioxane, t-butyl methyl ether, lower esters such as for example methyl acetate, ethyl acetate, propyl acetate, butyl acetate, halogenated solvents such as for example dichloromethane, chloroform, dichloroethan, alkanes such as for example benzene, toluene, xylene and water in the presence of HBr and any mixtures thereof.

Method A: Compound IV can be prepared as described m J. March, Adv. Org. Chem. _r 4th Ed., p. 411 by selective N-alkylation of racemic 2-chlorophenylglycin with alkylation agents, such as the halogen analogs (2- (2-thienyl) ethyl chlorrde, 2- (2-thienyl) ethyl bromide, 2- (2-thienyl) ethyl iodide, or 2- (2-thienyl) ethyl benzene sulfonate, or similar reactive sulfonates m an organrc solvent such as lower alcohols, nitπles, ketones, esters, halogenated hydrocarbons, amides, sulfoxides or mixtures thereof m the presence of organic bases (amines such as triethylamme and analogous ones) or inorganic bases (such as sodium hydrogen carbonate, sodium carbonate, sodium hydroxide and analogous ones) at a temperature from 0 °C to reflux temperature of the mixture at normal pressure or in an autoclave. Another possibility is to N-alkylate the compound 2- (2-thienyl) - ethylamme (compound with formula VIII) with 2-halo-2- (2- chlorophenyl) acetrc acid (as for example compound of formula IX) in the same manner.

Method B: Compound IV can be prepared by a selective reductive ammoalkylation as described in J. March, Adv. Org. Chem. , 4th Ed., p. 898. As reactants, 2- (2-thienyl) ethylamme and α- (2- chlorophenyl) -α-keto-acetic acid can be used and as reducing agents there can be used: i) hydrogen gas m the presence of an appropriate heterogeneous or homogeneous metal catalyst, wherein catalysts on the basis of palladium, platinum, nickel, cobalt, copper or an alloy (CuCr) can be used. Preferably, palladium or platinum on activated charcoal are used. As a reaction medium an appropriate nonreactive solvent, such as lower alcohols, nitπles, halogenated hydrocarbons, water or mixtures thereof, can be used; ii) reducing agents such as zinc in the presence of HCl, sodium cyano borohydπde, sodium triacetoxy borohydrrde, sodium borohydπde, iron pentacarbonyl, KOH in alcohol, BH3 in pyridine, formic acid or its salts with amines or metals, formamide, formalin m formic acid. The reaction with formic acid or its salts can be performed without or with a catalyst such as palladium or platrnum on activated charcoal.

In some cases rnstead of 2- (2-thienyl) ethylamme, its precursors such as nitro, nrtroso, azo compound or others can be used, which during the process are converted in situ into 2- (2- thienyl) ethylamme .

Alternatively, as a catalyst for reductive ammoalkylation palladium catalysts or catalysts with other noble metals (e.g. Pt, Ru, Rh, Ir) in a complex with other diphosphinic ligands such as (R, R) -norphos, (S, S) -chiraphos, (R, R) -deguphos, (R)- prophos, (R) -phos4-03 or srmrlar (such as described in J. Org. Chem., Vol. 68, no. 10, p. 1067, 2003) can be used. In this manner an optically pure dextro-rotary compound IV or at least a racemic mixture IV enriched with dextro-rotary isomer can be prepared, which facilitates the isolation of a proper form for the continuation of the preparation process to the final compound I .

Compound IV prepared in such a manner can be isolated as such or in the form of a salt with acids (hydrochloride and the like) or in the form of a salt with inorganic bases (sodium salt and the like) or organic bases (amines) .

The compound of formula IV, (±) -N- (2- (2-thienyl) ethyl) -2- chlorophenylglycm, as such or in salt form, can be further converted into the compound of formula III, (±) - (2-chloro- phenyl) ( 6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid, by cyclization analogous to the Pictet-Spengler synthesis by means of an appropriate Cl synthone or formylation reagents.

As Cl synthone there can be used: i) formaldehyde m the form of solutions m water or in an organic solvent or in a solvent mixture such as formalin, as well as compounds releasing formaldehyde in their degradation or decomposition such as various polymers of formaldehyde (paraformaldehyde) or hydrates; ii) compounds of the general structure XCH₂Y, wherein X represents a halogen atom, Ci to C₄ alkoxy group, Ci to C₄ alkylthio group or amine group, Y represents a Ci to C₄ alkoxy group, a Ci to C₄ alkylthio group, amine group, C2 to C₅ alkoxy carbonyl group or phenoxy carbonyl;

111) a six-membered heterocyclic compound in which CH₂ and Z group can be substituted, wherein Z can represent O, NH or S atom, such as S-trioxan; iv) 1, 3-dioxolane, 1,3-dioxane or S-analogs thereof.

The conversion (cyclization) can be performed m an inert organic solvent, water or m a mixture, as a reaction with formalin or a paraformaldehyde solution m formic acid. The basic substrate, i.e. the compound of formula IV, (±)-N-(2-(2- thienyl) ethyl) -2-chlorophenylglycin, can be used as such or in the form of a soluble salt e.g. hydrochloride. The reaction temperature depends upon the system used. Commonly, it is m the range between room temperature and the reflux temperature of the reaction mixture. However, in the case of very reactive reagents such as formaldehyde in formic acid, the reaction must be performed under cooling. In case of cyclization of compound of formula IV ( +) -N- (2- (2-thienyl) ethyl) -2-chlorophenylglycme milder conditions are used such as for example temperatures up to 30⁰C and two hours of the reactron time are enough to complete the reaction. In that case racemization of material is omitted. Isolation of the product is very simple as it could be crystallized as a formic acid salt by crystallization from water.

Alternatively, the compound of formula III, (±) - (2-chloro- phenyl) ( 6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid, can be prepared by N-alkylation of 4, 5, 6, 7-tetrahydrothieno [3, 2- c] pyridine with alkylation agents such as α-halo-2-chlorophenyl acetic acids such as α-bromo-2-chlorophenyl acetic acid, α- sulfonated derivatives of 2-chlorophenyl acetic acid such as α- benzenesulfonyl-2-chlorophenyl acetic acid, in an organic solvent such as lower alcohols, nitπles, ketones, esters, halogenated hydrocarbons, amides, sulfoxides, water or mixtures thereof in the presence of organic bases such as amines, preferably triethylamine, or of inorganic bases such as sodium hydrogen carbonate, sodium carbonate, sodium hydroxide and analogous ones, at a temperature from 0 ⁰C to the reflux temperature of the mixture, at a normal pressure or rn an autoclave .

The compound of formula III shows the X-ray powder diffractogram represented in Fig. 5 and the FT-IR spectrum represented in Fig. 6.

The thus obtained compound of formula III, (±) - (2-chlorophenyl) ( 6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid, can be isolated as such or converted into a salt such as a hydrochloride or acetate.

The hydrochloride of the compound III is showing the X-ray powder diffractogram represented in Fig. 7.

The acetate of the compound III is showing the X-ray powder diffractogram represented in Fig. 8.

The (±) - (2-chlorophenyl) ( 6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5- yl) acetic acid can be further resolved into both stereoisomers according to processes commonly known to the one skilled in the art. The general instructions for stereoisomer resolution are described in the literature such as J. March, Adv. Org. Chem. , 4th Ed., p. 120. In a concrete example, the stereoisomer resolution is preferably performed in such a manner that (±) - (2- chlorophenyl) (6, ^r7-dihydro-4H-thieno [3,2-c]piπd-5-yl) acetic acid is converted into a salt by the use of a strong chiral acid such as (IR)-(-)- or (IS) - (+) -camphor-10-sulfonic acid in an appropriate solvent, wherein preferably the crystallization of only one of both diastereoisomer salts occurs. By repeated recrystallization the purity of the salt increases and finally there is obtained the salt of formula II (-)-CSA, i.e. the salt of (+)- (2-chlorophenyl) ( 6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5- yl) acetic acid with (IR) -(-) -camphor-10-sulfonic acid when (IR)- (-) -camphor-10-sulfonic acid is used, or m the opposite case a salt of formula II (+) -CSA, which is the salt of (-) - (2- chlorophenyl) (6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid with (IS) -(+) -camphor-10-sulfonic acid, is obtained. As a solvent lower ketones, alcohols, esters, nitπles, mixtures thereof or mixtures with water can be used. Instead of (lR)-(-)- or (IS) - ( +) -camphor-10-sulfonic acid, (+ )- or (-) -tartaric acid can be used and then corresponding tartrates are formed. Useful acids for the separation can also be L- (-) -0, 0 ' -dibenzoyl tartaric acid, L- (+) -ascorbic acid, L- (+) -asparaginic acid, L- (+)-N-acetyl aspartic acid, L- (+) -aspartic/acid L-(+)- asparaginic acid, L- (+) -N-acetylasparaginic acid, L- (+) -glutamic acid, L- (+) -N-acetylglutamic acid or (S) - (-) -2- [ (phenylamino) - carbonyloxy] -propionic acid. (±) - (2-chlorophenyl) ( 6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl ) acetic acid, due to the presence of an amine group, also possesses acid properties m addition to alkaline ones, which can be useful for separation by the use of chiral bases such as brucme, ephedπne, strychnine, qumchomne, morphine and D- threo-2-amino-l- (4-nitrophenyl) -1, 2-propanediol .

The same method of racemic resolution can be used m case of using compound of formula IV for the preparation of (+) -N- (2- (2-thienyl) ethyl) -2-chlorophenylglycme as the mtermedate compound for the preparation of the compound with formula II.

The obtained salts of formula II.(-)-CSA or II.(+)-CSA can then be converted into compound II, (+)- (2-chlorophenyl) (6, 7-dihydro-

4H-thieno [3, 2-c] pyrid-5-yl) acetic acid, by hydrolysis according to conventional processes known to one skilled m the art. The compound of formula II can be prepared e.g. by the actron of sodium hydrogen carbonate rn ethyl acetate to the salts of formula II.(-)-CSA or II.(+)-CSA.

As a further alternative, the compound of formula II can be prepared by the reaction of the compound of formula XIII, an optically pure dextro-rotary form of 2-chlorophenyl glycrn, and the compound of formula VI, preferably 2- (2-thienyl) ethyl benzene sulfonate, analogously to the process for the preparation of the compound of formula IV according to the method A, and a further conversion, which is analogous to the conversion of the compound of formula IV into the compound of formula III.

Alternatively, the process for the preparation of the compound II can be performed in such a manner that in any synthesis step the stereoisomer resolution is performed provided that no damage to the chiral center, i.e. no racemization, occurs. This means that also from a racemic mixture of IV an appropriate isomer form can be resolved and thereafter an enantiomerically pure compound (dextro-rotary form) rs cyclized to the compound II according to one of the above-mentioned methods. The conversion of the compound II into the compound of formula I, clopidogrel, can according to the present invention be performed in several manners such as:

i) Alkylation with alkyl halides or alkyl sulfates

In particular, the alkylation can be performed according to the methods described in J. March, Adv. Org. Chem. , 4th Ed., p. 398. Thus, the sodium salt of the compound II can be used, which is converted to the compound I with methyl iodide or bromide. As a solvent any inert organic solvent can be used, the most appropriate ones being dipolar aprotic solvents such as HMPA, DMSO and DMF, at a temperature from 0 °C to the reflux temperature of the solvent, preferably at about room temperature. Instead of the sodium salt of the compound I any other salt with an inorganic ion such as potassium, silver or caesium salts, or a salt with an organic ion such as salts with amines can be used. Alternatively, an aromatic solvent such as benzene and toluene in the presence of an organic base such as DBU can be used. Instead of methyl iodide, other alkylating agents such as methyl chlorosulfite and methyl esters of sulfuric acid, sulfonic acid or other inorganic acids can be used. Such useful reagents for methylation are dimethyl sulfate and tπmethyl phosphate. Useful reagents for such type of methylation are also tπmethyl orthoformate (TMOF) and N, N- dimethylformamide dimethyl acetal (DMFDMA) .

Another alternative is the use of phase transfer catalysts in protic solvents and the use of methylation agents such as dimethyl sulfate as well as most of the others described above.

Preferably, as the methylation reagent according to this process trimethyl orthoformate and N, N-dimethylformamide dimethylacetal are used.

ii) Esterification with methanol in the presence of acids In particular, esterification can be performed according to the methods described e.g. m J. March, Adv. Org. Chem. , 4th Ed., p. 393. In this case the reaction of the compound II is performed with methanol as the alcohol component. The reaction is usually catalyzed with strong acids such as sulfuric acid, para-toluene sulfonic acid or hydrochloric acid, at a temperature from room temperature to the reflux temperature of the mixture, and at a normal or increased pressure by the use of an autoclave. As a strong acid also polymeric sulfonic acids can be used, which facilitates the isolation. The acid can also be replaced by a dehydrating agent such as DCC and analogous reagents or by molecular sieves.

in) Esterification with mixed anhydrides

In particular, esterification can be performed in such a manner that the previously prepared mixed anhydride of the compound II with another acid is converted with methanol into a methyl ester under the reaction conditions described in J. March, Adv. Org. Chem., 4th Ed., p. 393. For an effective conversion it is important that the formation of the methyl ester of the compound II is favoured over the formation of an ester with the other acid, and the reaction can be facilitated by the use of catalysts such as pyridine or DMAP (N,N-dimethylamino pyridine) . An appropriate mixed anhydride can be prepared by the reaction of acid anhydrides or chlorides with the compound II. In the reaction with acid chlorides the use of organic or inorganic bases binding the released chloride ion is desired. An example of such conversion is the formation of a mixed ester with methylchloroformate in the presence of tπethylamme as organic base in an inert solvent such as methylene chloride, methyl acetate, ethyl acetate or isopropylacetate under the cooling of the reaction mixture. After the completed conversion to a mixed anhydride, methanol is added and the mixture is heated to facilitate the reaction. The isolation of the compound I is easy since the side products are volatile or water-soluble. Methyl chloroformate could be replaced by the other analog reagents for the formation of mixed anhydrides known from the literature as are for example oxalyl chloride and pivaloyl chloride. IV) Esterification via acid halides

In this case the conversion is in particular performed via acid halides of the compound II, i.e. the chloride and possibly also bromide or iodide. Acid halides can be formed with thionyl chloride, which enables an easy isolation, but it is also possible to use phosphorous reagents of the structures PCI3 or

PCl₅ or bromine analogs. Also useful are oxy phosphorous analogs such as POCl₃ or PO₂Cl. Alternatively, a method with a mixture of

CCl₄ and PhP can also be used. In most cases also bromine and iodine analogs of said reagents are suitable.

The thus prepared halogen derivative of compound II is then treated with methanol, wherein the alcoholysis of the acid halide occurs. Optionally, an inorganic or organic base binding the released halide ions can be added to the reaction mixture.

Since in the presence of a strong alkaline medium there exists the possibility of an undesired racemization of the compound II or the product I, the reaction is performed in such a manner that the compounds are not subjected to strong alkaline conditions. As a solvent methanol can be used and optionally also an inert solvent such as methylene chloride can be added, which in the further course of the process also enables an isolation by extraction.

In the process according to the invention, preferably the process of esterification with mixed anhydrides is used for the conversion of the compound II into the compound I.

A further object of the present invention are new processes for the conversion of clopidogrel to pharmaceutically acceptable salts such as hydrogen sulfate, hydrochloride, (IR) - (-) -camphor- 10-sulfonate or (IS) - (+) -camphor-10-sulfonate .

Another object of the present invention is a new polymorphic form of clopidogrel (IR) -(-) -camphor-10-sulfonate, a process for its preparation and a pharmaceutical formulation containing this new form. The new polymorphic form of cLopidogrel (- ) -camphor-10-sulfonate is m particular characterized by an X-ray powder diffraction pattern having diffraction angles as represented m Table 1.

Table 1

Pos. d-spacmg ReI. Int.

No. [°2Th. ] [A] [%]

1 8.1 10.93 49

2 8.6 10.31 51

3 9.5 9.28 22

4 11.0 8.04 100

5 11.8 7.52 15

6 12.1 7.31 12

7 14.4 6.13 7

8 15.5 5.72 8

9 16.3 5.45 58

10 16.8 5.27 70

11 17.0 5.21 47

12 17.7 5.02 23

13 18.4 4.82 70

14 19.0 4.68 59

15 20.5 4.34 66

16 20.8 4.27 19

17 22.1 4.03 17

18 22.5 3.95 74

19 23.8 3.74 25

20 24.1 3.69 32

21 25.4 3.51 8

22 25.7 3.46 13

23 26.0 3.42 28

24 27.2 3.28 26

25 27.4 3.25 19

26 27.8 3.21 10

27 28.2 3.17 10

28 28.5 3.13 14

29 29.2 3.06 10 30 2 9 . 8 3 . 00 13

Characteristic diffraction angles for the new polymorphic form are represented in Table 2.

Table 2

Pos. d-spacing ReI. Int.

No. [°2Th. ] [A] [%]

1 8.1 10.93 49

2 8.6 10.31 51

3 11.0 8.04 100

4 16.3 5.45 58

5 16.8 5.27 70

6 18.4 4.82 70

7 19.0 4.68 59

8 20.5 4.34 66

9 22.5 3.95 74

10 24.1 3.69 32 11 26.0 3.42 28 12 27.2 3.28 26

The invention is therefore directed to clopidogrel (-) -camphor- 10-sulfonate having characteristic peaks in the X-ray powder diffraction pattern at 8.1, 8.6, 11.0, 16.3, 16.8, 18.4, 19.0, 20.5, 22.5, 24.1, 26.0 and 27.2.

The new form is in particular showing the X-ray powder diffractogram represented in Frg. 1 and the FT-IR spectrum given in Fig. 2.

A further object of the present invention is a new polymorphic form of clopidogrel (+) -camphor sulfonate, a process for its preparation and a pharmaceutrcal formulation containing this new form.

The new polymorphic form of clopidogrel (IS) - (+) -camphor-10- sulfonate is in particular characterized by an X-ray powder diffraction pattern having diffraction angles as represented in Table 3.

Table 3

Pos. d-spacing ReI. Int.

No. [°2Th.] [A] [%]

1 8.2 10.74 100

2 9.5 9.31 25

3 11.1 7.97 21

4 11.5 7.72 25

5 11.9 7.44 21

6 12.9 6.85 33

7 13.2 6.70 76

8 14.0 6.31 41

9 14.9 5.95 60

10 15.2 5.84 22

11 17.1 5.20 43

12 18.2 4.88 55

13 18.8 4.72 100

14 19.7 4.50 53

15 20.3 4.38 25

16 21.3 4.17 30

17 22.3 3.98 47

18 23.4 3.80 18

19 24.0 3.71 12

20 25.0 3.56 48

21 25.9 3.44 28

22 26.1 3.41 27

23 26.6 3.35 13

24 27.1 3.29 14

25 27.7 3.22 9

26 28.2 3.16 16

27 29.0 3.08 14

28 29.2 3.06 12

29 30.6 2.92 14 Characteristic diffraction angles for the new polymorphic form are represented in Table 4.

Table 4

Pos. d-spacing ReI. Int.

No. [°2Th. ] [A] [%]

1 8.2 10.74 100

2 13.2 6.70 76

3 14.0 6.31 41

4 14.9 5.95 60

5 17.1 5.20 43

6 18.2 4.88 55

7 18.8 4.72 100

8 19.7 4.50 53

9 22.3 3.98 47

10 25.0 3.56 48

The invention is therefore directed to clopidogrel (lS)-(+)- camphor-10-sulfonate having characteristic peaks in the X-ray powder diffraction pattern at 8.2, 13.2, 14.0, 14.9, 17.1, 18.2, 18.8, 19.7, 22.3 and 25.0.

This new form is in particular showing the X-ray powder diffractogram represented m Fig. 3 and the FT-IR spectrum given in Fig. 4.

The new polymorphic forms of clopidogrel (-) -camphor-10- sulfonate and clopidogrel (+) -camphor-10-sulfonate are preferably prepared by a process wherein clopidogrel base is dissolved in an organic solvent and a solution or solid form of (-)-camphor- 10-sulfonic acid or (+) -camphor-10-sulfonic acid is added.

The new polymorphic forms of clopidogrel (-) -camphor sulfonate and clopidogrel (+) -camphor sulfonate can further in particular be prepared by crystallization from organic solvents such as ketones, esters, alcohols, ethers and nitriles, mixtures thereof or mixtures with water. Preferably, there are used ketones such as acetone, methyl ethyl ketone and methyl iso-butyl ketone, esters such as methyl acetate, ethyl acetate, n-propyl acetate, iso-propyl acetate, iso-butyl acetate, alcohols such as ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol or ethers such as t-butyl methyl ether.

The crystallization of the new forms is preferably performed in such a manner that into a solution of clopidogrel in the form of a base in an appropriate solvent a solution of (IR) - (-) -camphor- 10-sulfonic acid or (IS) - (+) -camphor-10-sulfonic acid is carefully poured under stirring. After a certain time a corresponding salt i.e. clopidogrel (IR) - (-) -camphor-10- sulfonate or clopidogrel (IS) -(+) -camphor-10-sulfonate is crystallized. The isolation is put off until an appropriate solubility balance has formed and an appropriate amount of salt has crystallized (so-called "aging time") . The isolation is performed by the filtration of the mixture by vacuum, by overpressure or by centrifugation by means of suitably executed filtering devices. Then the cake is transferred from the filter to a dryer, which can be a vacuum dryer or an air dryer and it is dried to a constant mass or the necessary loss of solvent. The temperature during the drying can be room temperature or it can be increased to a temperature of about 70 ⁰C, yet it can be varied during drying, which usually improves the quality.

Optionally, the substance is suitably milled during or after drying to crush the clots or to improve the particle size.

The molar ratio between the clopidogrel base and the appropriate sulfonic acid can be from 0.5 : 1 to 1 : 0.5. However, m view of the salt stability and the yield, the most desired ratio is close to 1 : 1.

The isolation temperature and the concentration of the solvent or of both reagents depends upon the solvent used. In general, a good miscibility and filtrability of the mixture prior to isolation is required, and the yield is considered as well. A further object of the invention is also a process designated as Process A for the preparation of a polymorphic form I of clopidogrel hydrogen sulfate with suitable properties in view of preparing a pharmaceutical formulation. We have surprisingly found that the temperature and duration of addition of the sulfuric acid solution in an organic solvent, which is added to the clopidogrel solution in the same organic solvent substantially affects the particle size of the obtained clopidogrel sulfate. For the preparation of a suitably stable and technologically controllable pharmaceutical formulation in view of the selected technology, particles of suitable morphological properties and flowability are required. The morphological properties can be characterized by the particle size distribution, which can be e.g. bimodal or unimodal, or by the mean particle size of the whole population measured by laser diffraction. By the process of the present invention the particles with the desired distribution can be obtained by controlling the crystallization conditions.

The Process A accordrng to the invention for the preparation of the polymorphic form I of clopidogrel hydrogen sulfate comprises : i) adding a sulfuric acid solution in an organic solvent at T2 to a clopidogrel solution in an organrc solvent at Tl to obtain a suspension, ii) stirring the suspension after completed addition for a certain time at T3, in) heating the suspension to T4 under control with a certain heating speed and stirring at this temperature for a certain time, iv) isolating the precipitated product.

According to process A with the selection of particular technological parameters of crystallization according to the present invention the partrcles wrth appropriate flowable and morphological characteristics are obtained. Key technological parameters for the preparation of stable and easily technologically controlled substance suitable for the preparation of pharmaceutical composition are preferably the following, which can be independently selected from each other, and they form preferred embodrments of the process: a) concentration of clopidogrel in organic solvent, which is between 0.1 mol/L do 1 mol/L, b) concentration of sulfuric acid, which is between 1 mol/L to 4 mol/L, or concentrated sulfuric acid, c) temperature of solution of added sulphuric acid - T2, d) temperature of clopidogrel solution in organic solvent - Tl, e) temperature profile of crystallization step defined by temperatures T3 to T4, f) duration time of adding solution of sulfuric acid in step i) and time of stirring of suspension in step ii), which is less than 1 hour, g) moisture content in steps from i) to iv) during crystallization, which is between 0.1 w% to 1 w% .

Clopidogrel base used in the phase i) of the Process A is preferably extracted by a general known process into the same solvent as used in the steps i) through iv) . The advantage is that no complete evaporation of the solvent is required during the extraction step which has a great influence on production time and purity of the final product. At the same time the redundant water is removed by partial destilation to the moisture content as defined in paragraph g) .

The selected technological parameters as defined above increase the robustness of the process with the goal to prepare bigger particles of the final product as for example particles with the average size more than 10 μm.

The said selected technological parameters enable the preparation of particles with extraordinary flowable characteristics, wherein the tendency of clopidogrel salts toward electrostatic loading due to triboelectric effects is decreased, with at the same time the decrease of bulk volume below 6 inL/g. The temperatures Tl to T3 can be the same or different and are selected within temperatures from -30 °C to 40 ⁰C, preferably -

20 to 4O⁰C, more preferably from -10 ⁰C to 10 ⁰C. The temperature T4 can be from 0 °C to 40 °C, preferably from 15 °C to 25 ⁰C, and more preferably from 20° to 25°C.

The organic solvents can be aliphatic C3-C10 alcohols, C3-C8 esters, C3-C15 ketones or C₄ to Ci₅ ketone, preferably higher ketones, most preferably methyl isobutyl ketone.

The molar ratio between the added acid and the clopidogrel base is preferably between 0.8 and 1.2, in particular between 0.95 and 1.05.

We have found that the temperature at which a sulfuric acid solution in an organic solvent reacts with a clopidogrel solution m the same organic solvent decisively defines the kinetics of nucleation and agglomeration of the precipitate, which in connection with the manner and turbulence of stirring directly defines the particle size of clopidogrel hydrogen sulfate. For example, the addition of a cold sulfuric acid solution m an organic solvent into a cold clopidogrel solution in an organic solvent results in larger particles and agglomerates, whereas the addition of a sulfuric acid solution that was heated to room temperature prior to the addition into the clopidogrel solution in an organic solvent generally results in smaller particles, though said example is not limiting. On the basis of experience and a precise knowledge of system properties, in a controlled manner there can be prepared particles of clopidogrel hydrogen sulfate of form I with a mean size larger than lOμm, preferably larger than 20 μm, more preferably larger than 30μm, even more preferably larger than 50 μm and most preferably larger than 70 μm.

Thus, the above process is capable of producing such particles which form an embodiment of the invention.

Alternatively, the polymorphic form I of cloprdogrel sulfate with the desired properties can be prepared by the maceration in organic solvents slightly acidified with sulfuric acid according to the following general process according to the invention which is designated as Process B and comprises:

i) suspending clopidogrel hydrogen sulfate in an organic solvent containing dissolved sulfuric acid at temperature Tl, ii) stirring the suspension for a certain time at temperature T2, in) heating the suspension to T3 under control with a certain heating speed and stirring at this temperature for a certain time, iv) isolating the precipitated product.

The temperatures Tl and T2 can be the same or different and are selected within temperatures from -20 ⁰C to 40 ⁰C, preferably from -10 ⁰C to 10 ⁰C. The temperature T3 can be from 0 ⁰C to 40 ⁰C, preferably from 15 ⁰C to 25 ⁰C.

The organic solvents can be branched, straight-chain and/or cyclic hydrocarbons, preferably C3-C8 esters, C4-C15 or C3 to C15 ketones, preferably higher ketones, most preferably ethyl acetate and methyl isobutyl ketone. The concentration of sulfuric acid can be 0-4 mg/mL, preferably 0-2 mg/mL.

By the alternative Process B particles having exceptional flowability properties and an essentially decreased tendency of clopidogrel hydrogen sulfate to adhere to surfaces are obtained and the tendency of clopidogrel hydrogen sulfate towards electrostatic loading due to triboelectric effects is decreased. Said property can be evaluated by the bulk volume of the substance, which is of key importance for a stable and technological control of the material in the tablettmg process.

By the alternative Process B the bulk volumes can be decreased from more than 4 mL/g to less than 3 mL/g, preferably to less than 2.5 mL/g.

A further object of the present invention is the preparation of polymorphic form I of clopidogrel hydrogen sulfate wherein it is prepared by the Process A and the product is washed during the isolation phase by the organic solvents as defined above for the process B.

Thus, the invention relates to crystalline polymorphic form I clopidogrel hydrogen sulfate having a bulk volume of less than 3 mL/g.

A further object of the invention is a new form of clopidrogrel hydrogen sulfate, having characteristic absorption peaks at approximately 590, 721, 761, 884, 1043, 1079, 1189, 1223, 1321, 1436, 1479, 1652, 1750, 2560 and 2924 cm^"1 in the FT-IR spectrum, which is recorded by KBr-technique and is represented in Fig. 9

This new form is prepared according to a process comprising:

i) dissolving clopidogrel hydrogen sulfate m a polar protic solvent, ii) adding a less polar aprotic solvent, in) evaporating the solution to dryness under reduced pressure at a temperature from 30-60 °C, preferably from 40-50 ⁰C.

As the polar protic solvent, solvents such as alcohols, like methanol, ethanol and preferably methanol are selected. As the aprotic solvent, ketones such as acetone, diethyl ketone, ethyl methyl ketone, esters such as ethyl acetate, ethers such as isobutyl methyl ether, can be used.

We have surprisingly found out that this new form of clopidogrel hydrogen sulfate according to the present invention, can advantageously be used in Process B as a starting substance, which is then converted to form I of clopidogrel hydrogen sulfate having improved properties for direct tablettmg, i.e. a bulk volume of less than 2.5 mL/g.

A further object of the present invention is also a new polymorphic form of clopidogrel hydrochloride characterized by an X-ray powder diffraction pattern showrng characteristic diffraction angles (°2 Theta) at 9.5; 10.3; 14.3; 15.8 and 18.6, or d-spacings (A) 9.36; 8.57; 6.19; 5.62 and 4.76.

A further object of the invention is the use of Process A for the preparation of clopidogrel hydrochloride of polymorphic form I (as defined by WO 03/66637) and clopidogrel hydrochloride of new polymorphic form according to the present invention depending on selected temperature range and concentration of clopidogrel in an organic solvent. At Tl below approximately O⁰C, T3 and T4 lower than approximately 1O⁰C, preferably below 5°C and stirring time less than 2 hours at the before defined temperatures, clopidogrel hydrochloride prepared by the process A of the present rnvention gives the new polymorphrc form according to the present invention, while at temperatures T3 and T4 higher than approximately 5°C, preferably higher than 10⁰C and stirring time more than 2 hours, clopidogrel hydrochloride of already known polymorphic form I is obtained.

This new form of clopidogrel hydrochloride with suitable properties with regard to the use of the prepared clopidogrel hydrogen chloride in a pharmaceutical formulation of the present invention is prepared according to the process identical to

Process A of the present invention except that hydrochloric acid is used instead of sulfuric acid. In the process of the preparation of the new polymorphic form of clopidogrel hydrochloride identical key technological parameters of crystallization, as disclosed m the description of process A, are used, with the intention that new polymorphic form of clopidogrel hydrochloride prepared by process A of the present invention possesses same technological advantages as clopidogrel hydrogensulfate polymorphic form I.

According to process A of the present invention clopidogrel hydrochloride of polymorphic form I can be prepared wrth major difference that hydrochloride acid is used instead of sulfuric acid. In the process of the preparation of clopidogrel hydrochloride of polymorphic form I identical key parameters for crystallization are used as defined above for process A so that the obtained clopidogrel hydrochloride of polymorphic form I possesses same technological advantages as clopidogrel hydrogen sulfate of polymoprhic form I.

Particles of clopidogrel hydrochloride prepared by the process A according to the present invention are obtained in any polymorphic form with average particle size larger than lOμm, preferably larger than 20 μm.

According to the process A of the present invention clopidogrel hydrochloride of any polymorphic form can be prepared with HPLC purity more than 90%, preferably more than 95%, more preferably more than 99%.

According to the process A of the present invention clopidogrel hydrochloride of polymorphic form I and new polymorphic form of the present invention can be prepared with polymorphic purity more than 70%, preferably more than 90%, more preferably more than 95% and most preferably more than 99%.

The above described new polymorphic forms of clopidogrel salts, which are an object of the present invention, can be used as a therapeutic active substance, which together with a pharmaceutically acceptable carrier can be used as a medicament.

A further object of the present invention is a pharmaceutical formulation containing the new polymorphic forms of clopidogrel

(-) -camphor-10-sulfonate, clopidogrel (+) -camphor-10-sulfonate, clopidogrel hydrochloride. The invention also relates to pharmaceutical formulations containing the above described clopidogrel hydrogen sulfate according to the invention having a mean particle size of greater than 20μm or having a bulk volume of less than 3 ml/g. As pharmaceutically acceptable auxiliaries, substances generally known to one skilled in the art of pharmacy can be used.

The solid pharmaceutical compositions of the present invention preferably have a drssolution profile of not less then 70 % (Q) in 0.1 M Hydrochloric acid in 30 minutes. The formulations of the clopidogrel salts can be prepared by the use of known technological processes such as direct tabletting, wet granulation (with organic solvents e.g. MeOH, EtOH, acetone, isopropyl alcohol or mixtures thereof) , thermoplastic granulation, dry granulation or lyophilization.

For the preparation of formulations containing clopidogrel hydrogen sulfate, preferably the process of direct compressing is used. For the preparation of formulations containing clopidogrel camphor-10-sulfonate or clopidogrel hydrochloride, preferably the wet granulation process or the thermoplastic granulation process is used.

The direct compressing process can be performed in a manner that:

(a) the active substance is added to a mixture of excipients and it is compressed or

(b) the active substance is mixed together with excipients and it is compressed.

The wet granulation process can be performed in a manner that:

(a) a binder is dissolved or suspended in a solvent. It is also possible to use a pure solvent and the binder is added to the powder mixture in a dry state. Optionally, the active substance can also be dissolved in an organic solvent, possibly together with at least one auxiliary such as glidant, binder, filler;

(b) the granulating liquid, which can be the pure solvent or contains the dissolved/suspended binder or optionally the active substance and one or more auxiliaries, is sprayed onto the powder mixture in the wet granulation process;

(c) wet granulation can be performed in a high-shear mixer or a granulator, optionally in a low-shear mixer or a fluid-bed granulator/dryer;

(d) the granulate is dryed in a fluid-bed dryer, optionally in a tray dryer or in a dryer on the basis of vacuum or microwaves. The dry granulate is sieved, optionally also the wet granulate can be sieved. Preferably, one or more auxiliaries such as various pharmaceutically acceptable fillers, disintegrants, glidants, lubricants are added and it is compressed into tablets.

The thermoplastrc granulation process can be performed in a manner that :

(a) the active substance, polyethylene glycol and optionally also one or more auxiliaries such as fillers, glidants, disintegrants are mixed together; (b) it is heated to at least the melting point temperature of polyethylene glycol or to about 55-70 ⁰C, preferably to 58-68 °C;

(c) the material is cooled, sieved and to the granulate one or more auxiliaries such as various pharmaceutically acceptable fillers, disintegrants, glidants, lubricants are added and the mixture is compressed into tablets.

In all used technological processes of tablet making, especially in the case of clopidogrel chloride and clopidogrel hydrogen sulfate, a film coating process is preferably included due to their inconvenient organoleptic properties and also in order to achieve a better tablet appearance, an easier swallowing of the tablets as well as an easier packing of the tablets.

The coating can be a film coating on the basis of hydroxypropyl methyl cellulose (HPMC) , optionally HPMC + polyethylene glycol, optionally PVA (e.g. Opadry® II HP). The coatrng can be aqueous or by the use of organic solvents (e.g. Eudragit E dissolved in acetone/isopropyl alcohol) .

The coating is also desired in the case of clopidogrel camphor- 10-sulfonate, although its organoleptic properties are less sharp, and it can be incorporated into tablets without film coating.

If desired, m a solid pharmaceutical formulation also surfactants can be included. The surfactants can be selected from the group of nonionic or ionic surfactants or mixtures thereof . Suitable non-ionic surfactants are selected from the group of alkyl glucosides, alkyl maltosides, alkyl thioglucosides, lauryl macrogolglyceπdes, polyoxyethylene alkyl phenols, polyoxyethylene alkyl ethers, fatty acid polyethylene glycol esters, fatty acid polyethylene glycol glycerine esters, fatty acid polyoxyethylene sorbitane esters, polyoxyethylene- polyoxypropylene block copolymers, fatty acid polyglyceryl esters, polyoxyethylene glycerides, polyoxyethylene vegetable oils, polyoxyethylene hydrogenated vegetable oils, sterols and mixtures thereof. Preferred nonionic surfactants are fatty acid polyoxyethylene sorbitane esters, which are on the market under the trade names Polysorbate and Tween.

Suitable ionic surfactants are selected from the group of fatty acid salts, bile salt, phospholipides, phosphoric acid esters, carboxylates, sulfates, sulfonates and mixtures thereof. The preferred ionic surfactant is sodium lauryl sulfate.

The pharmaceutical composition of the invention in particular comprises 0.1-10 % by weight, preferably 0.1-5 % by weight of a surfactant .

A suitable mixing device in a direct compressing or in the above-described wet granulation, if desired, is a conventional device used for mixing active substances, excipients or a combination of active substance (s) and excipients. Conventional devices are motionless (passive) mixers, fluidized beds, diffusion, biconic diffusion, biconic, turbular, cubic, planetary, Y-, V-shaped mixers or high-shear mixers, drums etc. In the case of the above-described wet granulation, the device is selected from standard drying devices like a fluid-bed dryer, trays, a vacuum dryer, a dryer on microwave basis etc. In the case of thermoplastic granulation a high-shear mixer having a double wall with a heating medium (preferably water) in the intermediate space is used. During the thermoplastic granulation process the heating medium is heated so as to obtain the desired temperature of the powder mixture or the granulate in the mixer. The thermoplastic granulation can optionally also be performed m a fluid-bed granulator/dryer .

The pharmaceutical formulations according to the invention are preferably in a solid dosage form e.g. an immediate release dosage form, a rapidly soluble dosage form, a controlled release dosage form, a lyophilized dosage form, a sustained release dosage form, a prolongated dosage form, a pulse release dosage form, a mixed dosage form with immediate release and controlled release or a combination thereof.

The solid dosage form is preferably a tablet formulation, which can be coated if desired. The solid dosage form is preferably an immediate release dosage form, which is advantageous as to the bioavailability of the active compound.

If an immediate release dosage form is selected, it will be obvious to one skilled in the art that the amount of agent (s) for controlmg the release, either of a single one or of a mixture thereof, which should be used m the formation of the outer part, will be determined on the basis of different parameters such as the desired properties of releasing, which will include the amount of the active substance or the substance to be released, the desired rate of releasing the active substance or the substance and the size of micromatπx particles .

The pharmaceutical compositions according to the invention preferably include and in particular consist of: - 1-99 % by weight, preferably 5-50 % by weight, more preferably 5-15 % by weight of clopidogrel salt;

1-99 % by weight, preferably 20-99 % by weight, more preferably 50-99 % by weight of a diluent/flller;

- 1-90 % by weight, preferably 1-50 % by weight of a binder; - 1-50 % by weight, preferably 2-40 % by weight of a disintegrant or a superdismtegrant;

- 0.01-20 % of a glidant;

- 0.1-10 % of a lubricant: 0.1-10 % by weight, preferably 0.1-5 % by weight of a surfactant, and - 0.1-10 % of a film coated layer, if desired.

The excipients present in the composition of the invention can be diluents/fillers such as microcrystallme cellulose, powdered cellulose, lactose (anhydrous or monohydrate) , compressable sugar, fructose, dextrates, other sugars, such as mannitol, siliconised microcrystallinθ cellulose, calcium hydrogen phosphate, calcium carbonate, calcium lactate or combined diluents. Preferably, the excipients include at least one diluent selected from microcrystalline cellulose and lactose monohydrate .

The composition of the invention may also comprise binders such as povidone, microcrystalline cellulose, hydroxyethyl cellulose, hydroxpropyl cellulose, low-substituted hydroxypropyl cellulose (comprising 5-16 % by weight of hydroxypropyl groups), hydroxypropylmethyl cellulose or another cellulose ether, starch, pregelatimzed starch or polymethacrylate or a mixture of binders. It is preferable that the excipients include at least one agent having binding properties, selected from microcrystalline cellulose, hydroxpropyl cellulose, low- substituted hydroxypropyl cellulose, povrdone or ethyl cellulose.

In addition, there can also be present dismtegrants and/or superdismtegrants such as starch (e.g. corn starch, potato starch) , modified starches (sodium starch glycolate) , inodified cellulose (croscarmellose i.e. cross-linked sodium carboxymethyl cellulose) , cross-linked polyvinylpyrrolidone (crospovidone) , microcrystalline cellulose, sodium carboxymethyl cellulose, Amberlite®, alginic acid, sodium alginate, guar gum, gellan gum, Xanthan SM®. Microcrystalline cellulose if used as dismtegrant is preferably used in an amount of 0.5-15 % by weight. Preferably, the excipients include at least one dismtegrant or superdisintegrant selected preferably from crospovidone, croscarmellose and microcrystalline cellulose. In addition, as excipients also lubricants such as stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulfate, hydrogenated vegetable oil, hydrogenated castor oil, sodium stearyl fumarate, talc, macrogols can be present.

Preferably, the excipients include at least one lubricant selected preferably from sodium stearyl fumarate, stearic acid, hydrogenated vegetable oils or hydrogenated castor oil and macrogols .

The excipients may have several functions, i.e. an excipient can be a diluent and an additional binder, a binder and a disintegrant etc.

All stated examples (with clopidogrel chloride, clopidogrel camphor-10-sulfonate and clopidogrel hydrogen sulfate) can be film coated with conventional materials used for film coating. The film coating formulations usually contain the following components: polymer (s) , plasticizer (s) , colourant (s) /opaci- fier(s), vehicle (s). In a film coating suspension minor amounts of aromas, surfactants and waxes can be used. The majority of polymers used m film coating are either cellulose derivatives like cellulose ethers or acrylic polymers and copolymers. Occasionally included are high molecular weight polyethylene glycols, polyvinylpyrrolidone, polyvinyl alcohol and waxy materials .

Typical cellulose ethers are hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose. Acrylic polymers comprise a group of synthetic polymers with different functionalities. Some of them can be further modified to enhance the swelling and permeability by the incorporation of materials such as water soluble cellulose ethers and starches in order to ensure a complete disintegration/dissolution of the film.

The commonly used plasticizers can be categorized into three groups: polyols (glycerin, propylene glycol, macrogols), organic esters (phthalate esters, dibutyl sebacetate, citrate esters, triacetin) and oils/glycerides (castor oil, acetylated monoglycerides, fractionated coconut oil) .

The colourants/opacifiers are classified into several groups: organic dyes and their varnishes, inorganic colours, natural colours .

Description of the Drawings

Fig. 1: XRPD of clopidogrel (IR) - (-) camphor-10-sulfonate,

Fig. 2: FT-IR spectrum (KBr) of clopidogrel (IR) - (-) camphor-10- sulfonate,

Fig. 3: XRPD of clopidogrel (IS) -(+) camphor-10-sulfonate,

Fig. 4: FT-IR spectrum (KBr) of clopidogrel (IS) - (+) camphor-10- sulfonate,

Fig. 5: XRPD of (+)- (2-chlorophenyl) -6, 7-dihydro-4H-thieno [3, 2- c] pyrid-5-yl) acetic acid,

Fig. 6: FT-IR spectrum of (±) - (2-chlorophenyl) -6, 7-dihydro-4H- thieno [3, 2-c] pyrid-5-yl) acetic acid, Fig. 7: XRPD of (±) - (2-chlorophenyl) -6, 7-dihydro-4H-thieno [3, 2- c] pyrid-5-yl) acetic acid hydrochloride,

Fig. 8: XRPD of (±) - (2-chlorophenyl) -6, 7-dihydro-4H-thieno [3, 2- c] pyrid-5-yl) acetic acid acetate,

Fig. 9: FT-IR spectrum (KBr) of the new form of clopidogrel hydrogen sulfate,

Fig. 10: microscopic image of particles obtained according to

Example 1OA,

Fig. 11: microscopic images of particles obtained according to

Example 1OB. Fig. 12: microscopic images of particles obtained according to

Example HB.

Fig. 13: XRPD of clopidogrel hydrochloride obtained according

Example HD.

X-ray powder diffractograms were recorded on a Philips PW3040/60 X'Pert PRO diffractometer by the use of CuK_α-radiation 1.541874, and FT-IR spectra on a Perkin-Elmer Spectrum 1000 apparatus with the KBr method. Microscopic images were recorded with a Olympus BX 50 microscope, equipped with a Olympus DP70 camera. The mean particle sizes were measured on a Malvern, Mastersizer 2000 device in oil as the dispersion medium. The bulk volume measurements were performed according to European Pharmacopeia, chapter 2.9.15., Bulk volumes.

The present invention is illustrated by the following non- 1uniting Examples.

Examples

(+) -N- (2- (2-Thienyl) ethyl) -2-chlorophenyl glycine

Example IA

A mixture of (+) -2-chlorophenylglycine (0.1 mol, 18.56 g) , propionitπle (200 mL) , sodium hydrogen carbonate and 2- (2- thienyl) ethyl benzene sulfonate (0.12 mol, 32.20 g) was refluxed under stirring for 6 hours. The volatile components were evaporated and it was cooled and extracted with ethyl acetate at a pH of about 6. The organic phase was separated and the solvent was evaporated. 25.1 g of the crude title compound (85 % yield ) were obtained.

Example IB

A mixture of 2- (2-thienyl) ethyl amine (12.7 g, 100 mmol), ethanol (200 mL) , α- (2-chlorophenyl) -α-keto-acetic acid (18.4 g, 100 mmol) and 5 % of paladium on active charcoal (2 g) were hydrogenated at a pressure of 3 bar for 20 hours. The obtained reaction mixture was filtered and the volatile components were evaporated from the filtrate. 30 g of (±) -N- (2- (2-thienyl) ethyl) - 2-chlorophenyl glycine were obtained.

Example 1C

Crude (±) -N-2- (2-thienyl) ethyl) -2-chlorophenyl glycine prepared according to the example IA was dissolved in ethyl acetate and crystallized as hydrochloride in such a manner that into the solution about an equivalent amount of hydrogen chloride in ethyl acetate was added under cooling. The precipitate was stirred under cooling for 2 hours, then filtered and dryed m a vacuum.

23.2 g of white crystalline precipitate being (±) -N-2- (2- thienyl) ethyl) -2-chlorophenyl glycine in the form of hydrochloride were obtained (70 % yield) . Example ID

To the cold mixture of demineralised water (50 mL) , methanol (12.5 mL) , 2- (2-thienyl) ethylamine (7.0 g, 55 mmol) , and 2- bromo-2- (2-chlorophenyl) acetic acrd (12.5 g, 50 mmol) the solution of potassium hydroxyde (8.4 g in ) was slowly added. The mixture was stirred and heated to 40 °C for 4 hours. Then it was cooled, pH adjusted to 4 using 2M solution of hydrochloric acid and stirred for two hours at room temperature. The white precipitate (product) obtained was collected by filtration and washing by water and hexane . After drying 11.8 g of dry product

( (±) -N- (2- (2-thienyl) ethyl) -2-chlorophenylglycine) was obtained.

Melting point (microscope according to Kofler) : 180-182⁰C, IH-NMR (300 MHz, DMSO-d6, TMS): (ppm) = 2.76 (m, 1 H, CH2 ) , 2.91 (m, 1 H, CH2), 3.04 (m, 2 H, CH2), 4.73 (s, 1 H, CH), 6.86 (dd, J2 = 3.4 Hz, J3 = 1.1 Hz, thiophene), 6,93 (dd, Jl = 5.1 Hz, J2 = 3.4 Hz, thiophene), 7.3 -7.4 (m, 3 H, Ph, thiophene), 7.45 (m, 2 H, Ph) .

(+) -N- (2- (2-thienyl) ethyl) -2-chlorophenylglycine

Example 2

The mrxture of demineralised water (4 mL) , methanol (6 mL) , (±) - N- (2- (2-thienyl) ethyl) -2-chlorophenylglycrne (0.59 g, 2 mmol), and D-threo-2-amino-l- (4-nitrophenyl) -1, 3-propanediol (0.191 g, 0.9 mmol) was stirred and heated to 50°C for 1 hour. Then it was cooled while stirring for 2 hours. The obtained white precipitate (product) was collected by filtration and washing by water and hexane. After drying, 0.31 g of dried product was obtained. The solid was suspended rn water (20 mL) and pH adjusted to pH 4.5 using 1 M solution of hydrochloric acid. After stirring overnight, the solid was collected by filtration and dried in a vaccum dryer to constant weight. 0.22 g of product was obtained. IH-NMR (300 MHz, DMSO-d6, TMS): (ppm) = 2.76 (m, 1 H, CH2 ) , 2.91 (m, 1 H, CH2), 3.04 (m, 2 H, CH2), 4.73 (s, 1 H, CH), 6.86 (dd, J2 = 3.4 Hz, J3 = 1.1 Hz, thiophene) , 6,93 (dd, Jl = 5.1 Hz, J2 = 3.4 Hz, thiophene), 7.3 -7.4 (m, 3 H, Ph, thiophene), 7.45 (m, 2 H, Ph) .

(±) - (2-Chlorophenyl) -6,7-dihydro-4H-thieno [3,2-c]pyrid-5- yl) acetic acid

Example 3A

A mixture of crude (±) -N-2- (2-thienyl) ethyl) -2-chlorophenyl glycine (50 mmol, 14.79 g) prepared in Example IA was dissolved in formic acid (100 mL) . Paraformaldehyde (1 g) was added and the mrxture was heated under stirring to 70 ⁰C for 0.5 hour and then left to cool to room temperature in 2 hours. The mixture was poured onto ice and extracted with methylene chloride under pH adjustment to about 6 with sodium hydroxide. The organic layer was separated and thoroughly washed with water and the solvent was evaporated. The residue (13.8 g, 90 % yield) was the title compound.

Example 3B

(±) -N-2- (2-thienyl) ethyl) -2-chlorophenyl glycine hydrochloride (50 mmol, 16.6 g) , prepared as in Example IB was mixed with formalin (100 mL) and heated to 40 °C for 6 hours. The mixture was cooled to room temperature and extracted with methylene chloride under pH adjustment to about 6 with sodium hydroxide. The organic layer was separated and thoroughly washed with water and the solvent was evaporated. The residue (12.9 g, 84 % yield) was the title compound.

Example 3C

To a solution of CC-bromo-2-chlorophenyl acetic acid (25.0 g, 100 mmol) m methylene chloride (200 mL) , a solution of 4,5,6,7- tetrahydrothieno [3, 2-c] pyridine (13.9 g, 100 mmol) and triethylamine (22.2 g, 220 mmol) in methylene chloride (100 mL) was added dropwise under stirring. Then the mixture was slowly heated to reflux temperature for 5 hours. It was cooled to room temperature and extracted with water under acidifying to a pH of about 6 with hydrochloric acid. The organic layer was washed with water and the solvent was evaporated. 24.1 g of the product (78 % yield) were obtained.

Example 3D

An oily residue of example ID (+) -N-2- (2-thienyl) ethyl) -2- chlorophenyl glycmate) was then cyclized according to the process analogous to the Example 3A. To a solution of paraformaldehyde (0.2 g) in formic acid (20 mL) the oily residue from the previous step was added and the mixture was slowly heated to 40 °C for 3 hours under stirring. The mixture was poured onto ice and extracted with methylene chloride under pH adjustment to about 7 with sodium hydroxide. The organic layer was separated, thoroughly washed with water and the solvent was evaporated. Primarily (±) -methyl (2-chlorophenyl) -6, 7-dihydro-4H- thieno [3, 2-c] pyrid-5-yl) acetate was obtained. To the oil so obtained, 2 M sodium hydroxide solution (20 mL) was added and it was heated under reflux for 5 hours. Then the mixture was cooled and acidified with hydrochloric acid to a pH of about 6. It was further stirred for about 2 hours and the product was filtered off. 1.91 g of (±) - (2-chlorophenyl) -6, 7-dihydro-4H-thieno [3,2- c] pyrid-5-yl) acetic acid (62 % yield) were obtained. Melting point (microscope according to Kofler, uncorrected) : 108-112 °C, XRPD spectrum (Fig. 5), IR spectrum (Fig. 6), ¹H-NMR (300 MHz, DMSO-d6, TMS): (ppm) = 2.7-2.9 (m, 4 H, 2 x CH₂), 3.62 (dd, 2 H, CH₂, Ji=18Hz, J₂=15Hz), 3.95 (br s, 1 H, NH⁺), 4.65 (s, 1 H, CH), 6.76 (d, J = 5.2 Hz, IH, thiophen) , 7.25 (d, J = 5.2 Hz, IH, thiophen), 7.28-7.40 (m, 2 H, Ph), 7.44-7.48 (m, 1 H, Ph), 7.63-7.68 (m, 1 H, Ph) .

(+)-(2-Chlorophenyl)-6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl) acetic acid hydrochloride

Example 3E

(+) - (2-chlorophenyl) -6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid (13 g, about 3.2 mmol) prepared according to the process of Example 3A was dissolved in ethyl acetate and crystallized as hydrochloride in such a manner that into the solution an approximately equivalent amount of hydrogen chloride gas was introduced under cooling. The precipitate was stirred under cooling for some hours, then it was filtered off and dried in vacuum. 9.0 g of a white crystalline precipitate (82 % yield) were obtained. HPLC chrom. purity: 99.1 %, melting point (microscope accordrng to Kofler, uncorrected) : 184-187°C, XRPD spectrum (Figure I)₁ IR spectrum (cm¹): 2935, 2464, 1726, 1476, 1438, 1381, 1181, 1055, 925, 844, 755, 711; ¹H-NMR (300 MHz, DMSO-d6, TMS): (ppm) = 3.12 (s, 2 H, CH₂), 3.52 (s, 2 H, CH₂), 4.27 (s, 2 H, CH₂), 5.52 (s, 1 H, CH), 6.91 (d, J = 5.1 Hz, IH, thiophen) , 7.45 (d, J = 5.1 Hz, IH, thiophen) , 7.49-7.59 (m, 2 H, Ph), 7.63-7.69 (m, 1 H, Ph), 7.84-7.90 (m, 1 H, Ph); MS/MS (ES+): m/e = 308 (MH+), 198, 152.

(±) - (2-Chlorophenyl) -6,7-dihydro-4H-thieno [3,2-c]pyrid-5-yl) acetic acid acetate

Example 3F

(±) - (2-chlorophenyl) -6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid prepared according to the process of Example 3A was dissolved m ethyl acetate and crystallized as acetate in such a manner that into the solution an excess of acetic acid was introduced under cooling. The precipitate was stirred under cooling for some hours, then it was filtered off and dried in vacuum. 16.0 g of a white crystalline precipitate (87 % yield) were obtained. HPLC chrom. purity: 99.9%, melting point (microscope according to Kofler, uncorrected) : 118-123 °C, XRPD spectrum (Fig. 8), IR spectrum (cm¹): 2492, 1692, 1623, 1385, 1351, 1438, 1351, 1036, 891, 757, 748; ¹H-NMR (300 MHz, DMSO-d6, TMS) : (ppm) = 1.91 (s, 3 H, CH₃ - acetic acid), 2.90-2.79 (m, 4 H, 2 x CH₂), 3.65 (s, 2 H, CH₂), 4.73 (s, 1 H, CH), 6.78 (d, J = 5.1 Hz, IH, thiophen), 7.27 (d, J = 5.1 Hz, IH, thiophen), 7.42-7.35 (m, 2 H, Ph), 7.46-7.53 (m, 1 H, Ph), 7.60-7.68 (m, 1 H, Ph), 12.5 (m, 1 H, NH⁺) . (+)-(2-Chlorophenyl) -6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid (IR) -(- ) -camphor-10-sulfonate

Example 4A

(+) - (2-chlorophenyl) -6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid (9.23 g, 30 mmol) was dissolved in acetone (20 mL) .

To the solution a solution of (IR) - (-) -camphor-10-sulfonic acid

(4.65 g, 20 mmol) in acetone (20 mL) was poured, the mixture was cooled to 0-5 °C and seeded with a few crystals of the salt of

(IR) -(-) -camphor-10-sulfonic acid with (+)- (2-chlorophenyl) -6, 7- dihydro-4H-thieno [3, 2-c] pyrrd-5-yl) acetic acid. After some hours of stirring, the obtained salt (+)- (2-chlorophenyl) -6, 7- dihydro-4H-thieno [3, 2-c] pyrrd-5-yl) acetic acid (lR)-(-)- camphor-10-sulfonate was filtered by suction. After drying in vacuum, 7.12 g of the product (88 % yield) were obtained.

After repeated crystallization from acetone, 6.1 g of the product with >99.5 % content of (+) form of (2-chlorophenyl) -

6, 7-dihydro-4H-threno [3, 2-c] pyrid-5-yl) acetic acid were obtained.

Example 4B

In an identical manner as described in the previous Example, the crystallization from ethyl acetate was performed. The yield of the crude product was 72 %.

(+)-(2-Chlorophenyl) -6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid (IS) -(+) -camphor-10-sulfonate

Example 4C

(±) - (2-chlorophenyl) -6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5- yl) acetic acid (9.23 g, 30 mmol) was dissolved in acetone (20 mL) . To the solution a solution of (IR) -(-) -camphor-10-sulfonic acid (2.32 g, 10 mmol) in acetone (20 mL) was poured, the mixture was cooled to 0-5 °C and seeded wrth a few crystals of the salt of ( IS) -(+) -camphor-10-sulfonic acid with (+) - (2- chlorophenyl) -6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid. After some hours of stirring, the obtained salt was filtered off. After drying m vacuum 7.12 g of the product (84 % yield) were obtained.

After repeated crystallization from acetone, 6.1 g of the product with >99.5 % content of (+) form of (2-chlorophenyl) - 6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid were obtained.

Example 4D

In an identical manner as described in the previous Example, the crystallization from ethyl acetate was performed. The yield of the crude product was 69 %.

(+)-(2-Chlorophenyl)-6,7-dihydro-4H-thieno[3,2-c]pyrid-5- yl) acetic acid

Example 5A

A substance was prepared by the extraction of (+)-(2- chlorophenyl) -6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5-yl) acetic acid (IS) - (+) -camphor-10-sulfonate from the mixture ethyl acetate/water under maintaining the pH at about 6 by the use of a sodium hydrogen carbonate solution. By the extraction of 10 g of the mixture, 5.1 g of the product were obtained.

Example 5B

A mixture of (+)- (2-chlorophenyl) glycine (1.86 g, 10 mmol) , propionitπle (20 mL) , sodium hydrogen carbonate and 2- (2- thienyl) ethyl benzene sulfonate (3.22 g, 12 mmol) was heated under stirring. The reaction time was determined on the basis of the reaction mixture analysis. When the content of the starting compound was reduced below 1 %, the mixture was cooled and extracted with ethyl acetate at a pH of about 6. The organic phase was separated and the solvent was evaporated. 2.51 g of crude (+) -N- (2- (2-thienyl) ethyl) -2-chlorophenyl) glycine (85 % yield) were obtained. It was then cyclized according to the process analogous to the Example 3A. To a solution of paraformaldehyde (0.2 g) in formic acid (20 rnL) the product of the previous step was added and the mixture was slowly heated under stirring to 40 ⁰C for 3 hours. The mixture was poured onto ice and extracted with methylene chloride under adjustment of pH to about 6 with sodium hydroxrde. The organic layer was separated, thoroughly washed with water and the solvent was evaporated. The residual oil (2.37 g, 77 % yield) was the title compound.

Example 5C

Paraformaldehyde (1.55 g) was drssolved during heating in 20 ml formic acid. The mixture was cooled to 5°C, (+ )-N-(2-(2- thienyl) ethyl) -2-chlorophenylglycme (24.6 mmol, 7.25 g) was added and while stirring the solution was heated to room temperature. When the reaction was completed (defined by the analysis of the reaction mixture) the mixture was poured into 450 ml of cold water. The obtarned mixture was stirred for some additional hours m cold and the obtained crystalme product was collected. After drying 6.1 g of crude (+) - (2- chlorophenyl) (6, 7-dihydro-4H-thieno [3,2-c]pyπd-5-il) acetic acid m the form of formiate salt was obtained (70.2% yield). [α]²² _D = +46° (c=20 mg m 10 ml MeOH), HPLC enantiomeric purity more than 99.8%, ¹H-NMR (300 MHz, DMSO-d6, TMS): δ (ppm) = 2.74 - 2.92 (m, 4 H, CH₂CH₂), 3.4 (br s, NH⁺), 3.60 (d, J = 14,1 Hz, 1 H, CH₂), 3.69 (d, J = 14.1 Hz, 1 H, CH₂) , 4.72 (s, 1 H, CH), 6.77 (d, J = 5.1 Hz, IH, thiophen), 7.27 (d, J = 5.1 Hz, IH, thiophen) , 7.49 - 7.32 (m, 2 H, Ph), 7.48 - 7.52 (m, 1 H, Ph), 7.61 - 7.65 (m, 1 H, Ph), 8.14 (s, 1 H, HCOO^"), MS/MS (ES+): m/e = 308 (MH+), 198, 152.

(+) -Methyl (2-chlorophenyl) (6 ,7-dihydro-4H-thieno [3,2-c]pyrid-5- yl) acetate or clopidogrel

Example 6A

To a mixture of (+)- (2-chlorophenyl) (6, 7-dihydro-4H-thieno [3, 2- c] pyrid-5-yl) acetic acid (3.07 g, 10 mmol), N, N- dimethylformamide (10 mL) and triethylamme (3.03 g, 30 mmol) , methyl iodide (1.72 g, 12 mmol) was slowly added dropwise under stirring. It was stirred for further 5 hours and then the mixture was extracted with 50 mL of water and 10 mL of ethyl acetate. The organic layer was washed with water and the volatile components were evaporated. 2.8 g of the desired product in the form of an orl (88 % yield ) were obtained.

Example 6B

To a solution of acetyl chloride (2 mL) in methanol (50 mL) , (+) - (2-chlorophenyl) (6, 7-dihydro-4H-thieno [3, 2-c] pyrid-5- yl) acetic acid (3.07 g, 10 mmol) was added. The mixture was heated under reflux until the reaction was completed, which was confirmed by HPLC. The volatile components were evaporated and the residue was extracted with a mixture of ethyl acetate and water under the adjustment of pH to 7-8 with a sodium hydroxide solution. The organic layer was washed with water and the volatile components were evaporated. 2.9 g of the desired product in the form of an orl (91 % yield) were obtained.

Example 6C

(+) - (2-chlorophenyl) (6, 7-dihydro-4H-thieno [3, 2-c] pyπd-5- yl) acetic acid (3.07 g, 10 mmol) was dissolved m methylene chloride (60 mL) and methyl chloroformate (1.13 g, 12 mmol) was added under stirring. Then a mixture of triethylamme (2.1 mL,

15 mmol) and methylene chlorrde (40 mL) was added dropwise under stirring and cooling to 30 ⁰C. It was stirred for another hour at room temperature, whereupon 10 mL of methanol were slowly poured into the mixture and it was stirred for further 2 hours at room temperature and extracted with 30 mL of water under the adjustment of pH to 7-8 with a HCl solution. The organic layer was washed with water and the volatile components were evaporated. 2.8 g of desired product m the form of an oil (86 % yield) were obtained.

Example 6D (+) - (2-chlorophenyl) (6, 7-dihydro-4H-thieno [3, 2-c] pyπd-5- yl) acetic acid (3.07 g, 10 mmol) was dissolved in methylene chloride (60 mL) . The mixture was cooled to 0-5 ⁰C and a 2 %

NaOH solution (25 mL) and tetra-butylammonium bromide (160 mg, 0.5 mmol) were added thereto. The temperature of the reaction mixture was maintained under 20 ⁰C and dimethyl sulfate (1.64 g,

13 mol) was added dropwise under stirring. The stirring was continued for 12 hours at this temperature and then the mixture was extracted with 30 mL of water. The organic layer was once more washed with water and the volatile components were evaporated. 2.9 g of the desired product in the form of an oil

(89 % yield) were obtained.

Example 6E

To the solution of (+)- (2-chlorophenyl) ( 6, 7-dihydro-4H- thieno [3, 2-c] pyrid-5-yl) acetic acid hydrochloride (68.9 g, 0.20 mol) in methanol (0.30 L) concentrated sulfuric acid (64.0 mL) was added. The mixture was heated at reflux temperature. When the reaction was completed as concluded by in-process analysis, low boiling point fractions were removed by evaporation and the mixture was cooled. Then 0.40 L of water and 0.60 L of ethyl acetate were added. The mixture was stirred and pH adjusted to 8 using NaOH water solution while stirring. Then the organic phase was separated and washed for a few more times using water and NaOH solution for adjustment of pH to 8. The organic layer was once more washed with water and the volatile components were evaporated. 46.2 g of the desired product in the form of an oil were obtained.

Example 6F

To the solution of (+ )- (2-chlorophenyl) ( 6, 7-dihydro-4H- thieno [3, 2-c] pyrid-5-yl) acetic acid hydrochloride (5.145 g, 15 mmol) in methanol (22.5 mL) concentrated sulfuric acid (4.8 inL) was added. The mixture was heated at reflux temperature until the reaction was completed as juged by in-process analysis. Then volatile fraction was evaporated in vacuum, the mixture was cooled and 30 mL of water added. Then suspension of calcium hydroxyde (2.78 g) in 30 mL of water was added and filtered off after a few minutes of stirring. The cake was washed by water and water filtrate extracted with 45 mL of ethyl acetate after pH was adjusted to 8 using NaOH water solution. The organic layer was washed with water again and the volatile components were evaporated. 3.65 g of the desired product in the form of an oil were obtained.

Example 6G

To the mixture of (+) - (2-chlorophenyl) ( 6, 7-dihydro-4H- thieno [3, 2-c] pyrid-5-yl) acetic acid hydrochloride (0.689 g, 2 mmol) m l-methyl-2-pyrrolidone (6 mL) , water-free potassium carbonate (0.415 g, 3 mmol) methyl iodide (0.12 mL, 2 mmol) was added. The mixture was stirred for 18 hours and a new portion of methyl iodide (0.06 mmol, 1 mmol) was added and stirred overnight. Then 30 mL of water and 30 mL of ethyl acetate were added. The mixture was stirred and phases separated. The organic layer was washed with water and the volatile components were evaporated. 0.586 g of the desired product in the form of an oil was obtained.

Example 6H

To the mixture of (+)- (2-chlorophenyl) ( 6, 7-dihydro-4H- thieno [3, 2-c] pyrid-5-il) acetic acid in the form of hydrochloride (3.43 g, 10 mmol) m methylene chloride (100 ml) methyl chloroformate (2.08 g, 22 mmol) was added during stirring. To the obtained mixture during stirring and cooling to temperature of 30°C the solution of triethylamme (3.34 g, 33 mmol) and N, N- dimethylaminopyridine (0.61 g, 5 mmol) in methylene chloride (50 ml) was added dropwise. The solution was stirred for additional one hour at room temperature. To the obtained mixture 10 ml of methanol were slowly poured, then stirred for another 2 hours at room temperature and extracted wrth water. The organic phase was washed with water at pH adjusted to 5 with HCl solution and volatile components were removed. 2.8 g of the product in the form of an oil were obtained (90% yield) .

Example 61

To the mixture of methyl chloroformate (1.89 g, 20 mmol), tπethylamine (2.02 g, 20 mmol), N,N-dimethylaminopyπdine (0.24 g, 2 mmol) in ethyl acetate (100 mL) , the solution of (+) - (2- chlorophenyl) (6, 7-dihydro-4H-thieno [3, 2-c] pyπd-5-il) acetic acid hydrochloride (3.43 g, 10 mmol) in triethylamme (1.22 g, 12 mmol) in ethyl acetate (50 ml) was added dropwise during stirring and cooling to about 30⁰C. The obtained solution was stirred for another hour at room temperature, then to the mixture 5ml of methanol was slowly poured, stirred for 2 hours at room temperature and extracted with water. The organic phase was washed with water at pH adjusted to 5 wrth HCl solutron and the volatrle components were removed. 2.95 g of product in the form of an oil were obtained (92% yield) .

Clopidogrel (IR) - (-) -camphor-10-sulfonate

Example 7A

Clopidogrel (3.21 g, 10 mmol) was dissolved in acetone (15 mL) and a solution of (IR) -(-) -camphor-10-sulfonate (2.32 g, 10 mmol) m acetone (15 mL) was poured thereto and it was stirred at room temperature for 2 hours. The precipitate was filtered off, washed wrth fresh solvent and dried m vacuum. 4.55 g of the title compound were obtained. HPLC chrom. purity: >99.0 %, melting point (microscope according to Kofler, uncorrected) : 163-166 ⁰C, XRPD: Fig. 1, IR spectrum (cm ¹J : Fig. 2, ¹H-NMR (300 MHz, DMSO-d6, TMS): (ppm) = 0.74 (s, 3 H, CH₃), 1.04 (s, 3 H, CH₃), 1.27 (m, 2 H, CH₂), 1.76-1.98 (m, 3 H), 2.24 (m, IH), 2.39 (d, I H, J = 15 Hz), 2.66 (m, 1 H), 2.89 (d, I H, J = 15 Hz), 3.05 (s, 2 H, CH₂), 3.2-4.4 (m, 4 H, 2 x CH₂), 3.75 (s, 3 H, COOCH₃), 5.54 (s, 1 H, CH), 6.88 (d, J = 5.1 Hz, thiophen) , 7.43 (d, J = 5.1 Hz, thiophen), 7.48-7.59 (m, 2 H, Ph), 7.61-7.74 (m, 2 H, Ph) .

Example 7B

Clopidogrel (3.21 g, 10 mmol) was dissolved in ethyl acetate (15 mL) and a solution of (IR) - (-) -camphor-10-sulfonate (2.32 g, 10 mmol) in ethyl acetate (15 mL) was poured thereto and it was stirred at room temperature for 2 hours . The precipitate was filtered off, washed with fresh solvent and dried in vacuum. 4.87 g of the title compound having an identical IR spectrum and X-ray diffractogram as the compound prepared according to Example 7A were obtained.

Clopidogrel (IS) - (+) -camphor-10-sulfonate

Example 8A

Clopidogrel (3.21 g, 10 mmol) was dissolved in acetone (15 mL) and a solution of (IS) -(+) -camphor-10-sulfonate (2.32 g, 10 mmol) in acetone (15 mL) was poured thereto, then it was cooled to 0-5 °C, seeded with a few crystals of the final compound and stirred for further 2 hours under cooling. The precipitate was filtered off, washed with fresh solvent and dried in vacuum. 4.1 g of the title compound were obtained. HPLC chrom. purity: >99.0 %, melting point (microscope according to Kofler, uncorrected) :

143-148 °C, XRPD: Fig. 3, IR spectrum (cm^"1) : Fig. 4, ¹H-NMR (300

MHz, DMSO-d6, TMS): (ppm) = 0.74 (s, 3 H, CH₃), 1.04 (s, 3 H,

CH₃), 1.27 (m, 2 H, CH₂), 1.76-1.98 (m, 3 H), 2.24 (m, IH), 2.40

(d, I H, J = 15 Hz), 2.67 (m, 1 H), 2.89 (d, I H, J = 15 Hz), 3.05 (s, 2 H, CH₂), 3.2-4.4 (m, 4 H, 2 x CH₂), 3.75 (s, 3 H, COOCH₃), 5.55 (s, 1 H, CH), 6.87 (d, J = 5.1 Hz, thiophen), 7.43 (d, J = 5.1 Hz, thiophen), 7.48-7.59 (m, 2 H, Ph), 7.61-7.74 (m, 2 H, Ph) . Example 8B

Clopidogrel (3.21 g, 10 mmol) was dissolved in ethyl acetate (15 mL) , a solution of (IS) - (-) -camphor-10-sulfonate (2.32 g, 10 mmol) in ethyl acetate (15 mL) was poured thereto, it was cooled to 0-5 ⁰C for 2 hours and then stirred under heating to room temperature for 2 hours. The precipitate was filtered off, washed with fresh solvent and dried in vacuum. 4.2 g of the title compound having an identical IR spectrum and X-ray diffractogram as the compound prepared according to Example 8A were obtained.

Clopidogrel 2-propyl sulfate

Example 9

The mixture of (+) -methyl N- (2- (2-thienyl) ethyl) -2- chlorophenylglycme (13.85 g_Λ 40 mmol) and 37% solution of formaldehyde (42 mL) was heated to about 5O⁰C until the reaction was complete as decided by m-process analysis. To the obtained mixture ethyl acetate (120 mL) and 8% sodium hydrogencarbonate solution (60 mL) were added and stirred for half one hour. Phases were separated and the organic phase washed with 5% solution of sodium hydrogene sulfite and water. The solution was then treated with decoulorizmg carbon and anhydrous sodium sulfate and filtered. The obtained clear liquid was evaporated to the coulorless oil. The oil was dissolved m 2-propanol (50 ml), then concentrated sulfuric acid (2.3 mL) was added and the mixture was refluxed for 2 hours. Then it was cooled while stirring for 2 hours. The obtained white precipitate was collected by filtration and washing. After drying in an air dryer 13.8 g of the product were obtained. Melting point (microscope according to Kofler) : 158-163°C, FT-IR spectrum (KBr, cm-1) : 1755, 1265, 1226, 1037, 935, 867, 618, IH-NMR (300 MHz, DMSO-d6, TMS): (ppm) = 1.12 (d, J = 6.3 Hz, 6 H, 2x CH3), 3.6 - 4.2 (m 6 H, 3x CH2), 3.76 (m, 3 H, CH3) , 4.27 (m, J = 6.3 Hz, 1 H, CH), 5.59 (s, 1 H, CH), 6.89 (d, J = 5.4 Hz, thiophene), 7.44 (d, J = 5.4 Hz, thiophene) , 7.5 -7.6 (m, 2 H, Ph), 7.65 - 7.72 (m, 2 H, Ph).

Clopidogrel hydrogen sulfate

Example 1OA

7.05 g of clopidogrel base were drssolved in 100 mL of methyl isobutyl ketone (MIBK), 1.1 mL of drchloromethan was added thereto and the solution was cooled to -7 ⁰C. A sulfuric acid solution was prepared at -10 °C by adding 2.5 mL of 98 % sulfuric acid to 100 mL of MIBK in about 30 minutes. 40 mL of the prepared sulfuric acid solution were added to the solution of clopidogrel base at -7 ⁰C in 2 hours. At the time of addition to the clopidogrel base solution, the sulfuric acid solution was heated from a temperature between -5 ⁰C and 5 ⁰C to the temperature of 20 ⁰C. The suspension was stirred at -7 ⁰C for 3 hours, then it was heated to 17 °C within 8 hours and then to 20 °C within further 10 hours. The product was filtered on a vacuum filter and washed with MIBK. The product was dried in a flow of dry air for some hours and then heated to 50 °C and drred in vacuum for 3 hours. 7.48 g of a dry product (82 % yield) were obtained. A microscopic image of the partrcles of the obtained product is shown in Fig. 10. The mean particle size is 35 μm with the following particle size drstribution : 10 % of particles smaller than 12.2 μm, 50 % of particles larger than 31.7 μm and 90 % of particles smaller than 60.8μm.

Example 1OB

3 kg of clopidogrel hydrogen sulfate were suspended in 13 L of MIBK. 20 L of a saturated NaHCCb solution were added thereto and the clopidogrel base was extracted with MIBK. The extraction of water phase was repeated with 8 L of MIBK. The organic layers were combined, washed with water and evaporated to an oily residue. The oily residue was dissolved with 32 L of MIBK and 0.32 L of methylene chlorrde were added thereto, whereupon the solution was cooled to -7 °C. In another vessel 0.34 L of 98 % sulfuric acid was dissolved in 13 L of MIBK at -10 °C within 1 hour. The acid solution was maintained at the temperature of -7 °C and then it was added to the solution of clopidogrel base within 3 hours. At the time of addition the temperature of the sulfuric acid solution was maintained below 0 °C. After completed acid addition the suspension was stirred for 3 hours, then heated to 17 °C within 8 hours, whereupon the temperature was raised to 25°C in the next 10 hours. The suspension was filtered on a vacuum filter and washed twice with 10 L of MIBK. The product was dried under the flow of dry nitrogen for 3 hours and sieved. Then the product was dried at 50-60 ⁰C for 5 hours and sieved again. 2.165 kg of the product were obtained. A microscopic image of the particles of the obtained product is shown in Fig. 11. The mean particle size was 75 μm with the following particle size distribution: 10 % of particles smaller than 8.6 μm, 50 % of particles larger than 52.3 μm and 90 % of particles smaller than 130.5 μm.

Example 1OC

I g of clopidogrel hydrogen sulfate was dissolved in 1 mL of methanol and to the solution 1.5 mL of diethyl ketone were added. The solution was slowly evaporated to dryness under reduced pressure at a temperature of 50 °C. The obtained product was characterized by FT-IR spectrum: IR spectrum (cm¹): 590, 721, 761, 884, 1043, 1079, 1189, 1223, 1321, 1436, 1479, 1652, 1750, 2560 and 2924 cm¹. Chromatographic HPLC purity was greater than 99.5 %.

Example 1OD

260 g of clopidogrel 2-propyl sulfate were suspended in 2100 mL of methyl isobutyl ketone and 780 mL of water were added. The suspension was stirred and pH was set to 7.5 to 8 with slow addition of IM NaOH. The obtained mixture was stirred and phases were separated. The organic layer was thoroughly washed with 780 mL of water about 3 times. The solution of clopidogrel base in methyl isobutyl ketone was evaporated by vacuum distillation until 90 % of solvent were removed. The amount of clopidogrel base was determined and dissolved in methyl isobutyl ketone so that the total amount of solvent was 2600 mL. The solution was filtered and cooled to -7°C and 31 mL of methylene chloride were added. While stirring (overhead stirrer) the solution of 98% sulfuric acid (53 g) in 860 mL of methyl isobutyl ketone was added within about 3 hours. After this addition was complete, the suspension was stirred for about 3 hours at 0°C. Then the temperature was raised to 17 ⁰C in 8 hours, followed by slow heating to 25 ⁰C m 10 hours. Clopidogrel hydrogen sulfate form I was collected.

The material was dried in a fluid bed dryer at 20 and 30 °C. When the temperature of the material was constant, the product was sieved and the material was further dried while stepwise rising the air temperature to 50 - 55 °C. Yield: 89%, Characteristic XRPD peaks show polymorphic form I, HPLC purity 99.8, average particle size: 34 μm, bulk density: 2.5 mL/g, residual MIBK less then 2500 ppm.

Example 1OE

5.0 g (loss on drying 4.6%) of clopidogrel base were dissolved m 100 mL methyl isobutyl ketone and filtered trough 0.45 μm filter into a 250 mL reactor equipped with an overhead stirrer. The clear solution was cooled to -7 °C. While stirring at that temperature 0.76 mL of 98% sulphuric acid were drop-wise added to the solution in 3 hours. A suspension was formed and stirring at -7°C was continued for 3 hours after the addition. Then the temperature was slowly raised to 25 ⁰C m 8 hours, and nucleation was observed. The suspension was stirred for 10 hours at 25°C to get well crystallized clopidogrel hydrogen sulfate form I suspension. The product was collected, washed with 15 mL of acetone, dried m a vacuum dryer at 25 °C for 10 hours and sieved trough a rough grid. Then the drying was continued and the temperature was raised to 30 ^CC for 2 hours, followed by drying at temperature of 40°C for 3 hours, and subsequently the product was sieved through a fine grid. Finally the product was dried for 4 hours at 50°C. Yield: 5.2 g, XRPD: form I, average particle size: 50 μm. Bulk density: 3.0 mL/g , HPLC purity: 99.7%, residual MIBK 400 ppm. Clopidogrel hydrochloride

Example HA

2 g of clopidogrel base was dissolved in 38 mL of diethyl ketone and cooled to -10 °C. To the solution stirred with a magnetic stirrer, a solution of HCl in diethyl ketone (6.5 mL of a solution prepared by dissolving 1.5 g of HCl gas in 40 mL of DEK) was added dropwise. The addition was completed after approximately 30 minutes. During the addition the temperature was maintained below -5 °C and after the addition the suspension was heated to 10 ⁰C. The precipitate was filtered at room temperature and washed with 15 mL of DEK. The obtained product was dried in vacuum at 40 ⁰C for 2 hours. 1.52 g of the product were obtained. Chromatographic HPLC purity was greater than 99.5 %. Characteristic XRPD diffraction angles were: 9.5,0, 10.3, 14.3, 15.8, 18.6 °2 Theta.

Example HB

Clopidogrel hydrochloride in amorphous form was suspended in 60 mL diethylketone at 40⁰C. The obtained suspension was heated to 60°C and cooled to 20°C in 45 minutes. The obtained crystals were stirred for approximately 2 hours at temperature 20°C and collected by filtration. The product was dried in a vacuum drier for 2 hours. 1.2 g of product were obtained with morphology and particle size as it is shown in Fig. 12. The parameters of unit cell are: a=9.3A, b=8.9A. c=21.0A, β=90,4°, the characteristic XRPD peaks are 9.5; 10.3; 14.3; 15.8; 18.6 °2Theta. The estimated bulk volume is between 1.8 and 2.3 ml/g.

Example HC

0.48 g of clopidogrel base were dissolved m 9.0 mL methyl isobutyl ketone at 25 ⁰C and filtered. The obtained solution was cooled at -30 °C and gaseous HCl was added during intensive stirring. The dense suspension was left for 2 hours at a temperature of -30⁰C. The product was collected by filtration and washed with 8 mL diethyl ether and dried m vacuum. The obtained product had a melting point of 133-135°C. The characteristic XRPD peaks are 9.5; 10.3; 14.3;15.8; 18.6 °2Theta.

Example HD

Clopidogrel base (36.18 g) was dissolved in ethyl acetate (253 mL) . The obtained solution was charged into a reactor with overhead stirrer (moisture content < 0.2 %) and cooled to 0 ⁰C.

During intense stirring 1-2 M HCl in ethyl acetate was added

(4.31 g HCl m 55 mL solution) to the solution of clopidogrel base during 2 to 3 hours. The obtained suspension was stirred for 2 hours at temperature 0 °C, then the reactor was heated to 5⁰C during 2 to 3 hours. The suspension was crystallized at temperature of 5°C for additional 2 hours. The product was collected by filtration and washed with ethyl acetate. The product was dried under nitrogen at 20-25°C for 3 hours, then the product was sieved and further dried m a vacuum drier at 40^cC for 2 hours. Yield was 36.38 g, the average particle size was 25 μm, bulk volume was 4.6 mL/g, chromatographic HPLC purity is 99.7%, characterrstic XRPD peaks show polymorphic form I (Fig 13) .

Example HE

Clopidogrel base (5 g) was dissolved m 75 mL isopropyl acetate. The obtained solution was filtered into a reactor and the filter was washed with 25 mL isopropyl acetate. The solution was cooled to 0°C and 1 M solution of HCl in isopropanol (0.595 g in 15.1 mL solution) was added during stirring in 3 hours. The obtained suspension was further stirred at 0⁰C for 3 hours, then the temperature was raised to 20 °C in 10 hours. The product was collected by filtration and washed with isopropyl acetate. The obtained product was dried in a vacuum drier at 20°C for 3 hours, and subsequently for additional three hours at 40⁰C. Yield: 3.87 g, the average particle size 31 μm chromatographic HPLC purity is 99.8%, characteristic XRPD peaks show polymorphic form I (corresponds to Fig 13.) . Example H F

23.4 g of clopidogrel isopropyl sulphate (or equimolar amout of chloride, camforsulphonate, hrdrogensulphate salt) were suspended in 187 mL of ethyl acetate and 61 mL of water were added. The suspension was stirred at 20-25°C and the pH was set to 7.5 to 8 by slow addition of IM solution of NaOH. The mixture was stirred for 1 hour, then phases were allowed to separate. The organic layer was collected and thoroughly washed with 70 mL of water about 3 times. About 70-80% of solvent were evaporated by vacuum distillation. The residue was taken into 70 to 100 mL of ethyl acetate, and the solution was filtered and cooled to 0°C. While stirring 1-2 M solution of HCl in ethyl acetate was added (1.9 g HCl in 30 mL of ethyl acetate) to the solution of clopidogrel base m ethyl acetate m about 2-3 hours. The suspension was stirred (overhead stirrer) at 0⁰C for 2 hours, then the temperature was raised to 20 °C in 3 hours. The suspension was additionally stirred at 20°C for 4 hours, and the product was collected by filtration and washed with 11 mL of ethyl acetate. The product was dried at 20-25⁰C for 3 hours and sieved trough a 3x3 mm grid. Vacuum drying was continued for 2 hours at 40°C and 4 hours at 50⁰C and finally at 60⁰C until dryness. Yield: 92%, characteristic XRPD peaks show polymorphic form I (coressponds to Fig 13.), HPLC purity: 99.8%, average particle size: 10 μm.

Examples of pharmaceutical formulations

The stated examples of formulations can be used for the preparation of formulations with different salts of clopidogrel. The selected salts are prepared by the processes according to the present invention or by processes described in the literature stated herein m the introductory part. The salts can be selected, without limitation, from camphor-10-sulfonate, hydrogen sulfate, hydrochloride, hydrobromide, mesylate, bezylate, napsilate. Example Fl

The formulation was prepared by the drrect tabletting process,

Example F2

The granules were prepared according to the thermoplastic granulation process in a high-shear mixer with a double wall and a heating medium between the walls.

Example F3

Example F4

Granulate according to Example F2 176.837

Macrocrystalline cellulose, Avicel

PH 112 68.463

Kollidon CL 15.000

Aerosil 0.700

Stearic acid 9.000

Total 270.000

Example F5

Granulate according to Example F2 176.837

Microcrystalline cellulose, Avicel

PH 112 72.263

Kollidon CL 17.000

Aerosil 0.700

Sodium stearyl fumarate 3.200

Total 270.000

Example F6

[mg/tablet]

Clopidogrel-10 -sulfonate

(corresponds to 75 mg of clopidogrel) 129. 137

Macrogol 6000 25 .00

Aerosil 0 .70

Microcrystalline cellulose PH112 22. 000

The granulate was prepared according to the thermoplastic granulation method in a fluid-bed granulator/dryer . Example F7

The tabletting mixture can be, with regard to the composition and the preparation manner, prepared entirely eguivalently as in the case of thermoplastic granulation in a high-shear mixer (e.g. Examples 3, 4, 5) .

Example F8

Example F9

*evaporates in the technological process

The granulate was prepared by wet granulation in a high-shear mixer and dried in a fluid-bed dryer.

Example FlO

Example FIl

Example F12

^evaporates in the technological process

The granulate was prepared by wet granulation according to high- shear method; fluid-bed drying.

Example F13

The granulate was prepared by wet granulation in a high-shear mixer and drying in a fluid-bed dryer. Example F14 (granulate)

The granulate was prepared according to thermoplastic granulation method in a high-shear mixer with a double wall and a heating medium between the walls.

Example F15

Example Fl 6

Example F17

Example F18

Example F19 (granulate)

The granulate was prepared according to thermoplastic granulation method in a fluid-bed granulator/dryer . The tabletting mixture can be, with regard to the composition and the preparation manner, prepared entirely equivalently as in the case of thermoplastic granulation in a high-shear mixer (e.g. Examples 15, 16, 17, 18) . Example F20 (granulate)

The granulate was prepared according to thermoplastic granulation method in a fluid-bed granulator/dryer .

Example F21

Example F22 (granulate)

The granulate was prepared according to thermoplastic granulation method in a high-shear mixer with a double wall and a heating medium between the walls. Example F23

Example F24

Example F25

Example F26

Granulate according to Example F22 122 .20

Microcrystalline cellulose, Avicel

PH 112 126 .90

Kollidon CL 17. 00 Aerosil 0.700

Sodium stearyl fumarate 3.20

Total 270.000

Example F27

Granulate according to Example F22 122.20

Microcrystalline cellulose, Avicel

PH 112 123.10

Kollidon CL 15.00

Aerosil 0.700

Stearic acid 9.00

Total 270.000

All stated Examples (either with clopidogrel hydrochloride, clopidogrel camphor-10-sulfonate or clopidogrel hydrogen sulfate) can be film coated with conventional materials used for film coating. Film coated formulations usually contain the following components: polymer (s) , plasticizer (s) , dye(s), opacifier (s) , vehicle (s). In the film coating suspension small amounts of aromas, surfactants and waxes can be used. The majority of polymers used in film coating are either cellulose derivatives such as cellulose ethers or acrylic polymers and copolymers. Occasionally, high molecular weight polyethylene glycols, polyvinylpyrrolidone, polyvinyl alcohol and waxes are used.

Example of film coating composition (water coating)

Example F28

Tablet (cores) 270.00

Opadry AMB 7.947 Iron oxide red q.s. Example F29

Example F30

Tablet (cores) 270.00

Opadry II HP 7.96 Iron oxide red q.s.

Example F31

Tablet (cores) 270.00

AquaPolish® 7.96 Iron oxide red q.s.

Example F32

Example F33

Tablet (cores) 270.00

Eudragit EPO 4.50

Example F34

Example F35

Example of film coating composition (coating by the use of organic solvents: isopropyl alcohol/acetone)

Example F36

Example of film coating composition (coating by the use of organic solvents: ethanol or combination of ethanol/water)

Example F39

Examples F40 - F44

Method of preparation:

Clopidogrel hydrochloride, cellulose, microcrystalline, srlrca, colloidal, anhydrous (Aerosil) and PEG (Macrogol) 6000 were continuously mixed while heated in a double wall container of a high-shear mixer. Due to the contact with the warm wall (hot water in a double wall compartment) and the mixing process as well, the mixture was heated to approximately 58 - 65°C, when the melting of PEG 6000 starts. This led to the agglomeration process of fine powder particles of active ingredient and PEG 6000. Such material was then cooled down (in a fluid bed dryer, on trays or other method) and sieved. Cellulose, microcrystalline, crospovidone (Kollidone CL) , silica, colloidal anhydrous (Aerosil) , and one or more lubricant (talc or castor oil, hydrogenated, or combination of talc and castor oil, hydrogenated or castor oil and PEG (Macrogol) 6000), were mixed with the granulate and the compression mixture was compressed into tablets.

The used silica, colloidal, anhydrous (Aerosil) can be hydrophilic (for instance Aerosil 200) or hydrophobic type (for instance Aerosil R972 Pharma) . The tablets were then film coated, using water based or organic based coating (preferably ethanol) or combinations of water/organic coatings.

The used API m the described process can have a relatively small mean particle size or relatively large particle size (for instance 5- 15 μm or above 50 μm, or above 60 μm) .

Claims

C la ims

1. A process for the preparation of clopidogrel of formula I comprising: a) converting compound of formula II, (+) - (2-chlorophenyl) (6,7- dihydro-4H-thieno [3, 2-c] pyrrd-5-γl) acetrc acid, according to any process selected from: i) alkylatron with alkyl halides or alkyl sulfates, ii) esterrfrcation with methanol in the presence of acids, iii) esterrfication with mixed anhydrides, iv) esterification via acid halides to clopidogrel of formula I and b) optronally convertrng the cloprdogrel rnto a pharmaceutrcally acceptable salt thereof.

2. A process for the preparatron of clopidogrel accordrng to claim 1 comprising the preparation of a compound of formula II according to any process selected from: i) conversron of the compound of formula IV, racemic, optically pure or partially enriched (+) -N- (2- (2-thienyl) ethyl) - 2-chlorophenylglycrn, vra compound III, racemrc or optrcally pure or partially enrrched (+ )- (2-chlorophenyl) ( 6, 7-drhydro-4H- thieno [3, 2-c] pyrid-5-yl) acetic acid, wherein, if necessary, optical resolution can be performed rn any step; ii) reaction of the compound of formula XIII, optically pure dextro-rotary form of 2-chlorophenyl glycin and the compound of formula VI, 2- (2-thienyl) ethyl benzene sulfonate.

3. Polymorphrc form of clopidogrel (-) -cainphor-10-sulfonate of a high purity, havrng characterrstrc peaks in the X-ray powder diffraction pattern at 8.1, 8.6, 11.0, 16.3, 16.8, 18.4, 19.0, 20.5, 22.5, 24.1, 26.0, 27.2 °2Theta.

4. Polymorphrc form of cloprdogrel (-) -camphor-10-sulfonate accordrng to claim 3, having peaks in the X-ray powder diffraction pattern at 8.1, 8.6, 9.5, 11.0, 11.8, 12.1, 4.4, 15.5, 16.3, 16.8, 17.0, 17.7, 18.4, 19.0, 20.5, 20.8, 22.1, 22.5, 23.8, 24.1, 25.4, 25.7, 26.0, 27.2, 27.4, 27.8, 28.2, 28.5, 29.2, 29.8 °2Theta.

5. Polymorphic form of clopidogrel (-) -camphor-10-sulfonate according to claims 3 or 4, havrng an X-ray powder diffractogram as given in Fig. 1.

6. Polymorphic form of clopidogrel (+ ) -cainphor-10-sulfonate of a high purity, having characteristic peaks in the X-ray powder diffraction pattern at 8.2, 13.2, 14.0, 14.9, 17.1, 18.2, 18.8, 19.7, 22.3, 25.0 °2Theta.

7. Polymorphic form of clopidogrel (+) -camphor-10-sulfonate according to claim 6, having characteristic peaks in the X-ray powder diffraction pattern at 8.2, 9.5, 11.1, 11.5, 11.9, 12.9,

13.2, 14.0, 14.9, 15.2, 17.1, 18.2, 18.8, 19.7, 20.3, 21.3,

22.3, 23.4, 24.0, 25.0, 25.9, 26.1, 26.6, 27.1, 27.7, 28.2, 29.0, 29.2, 30.6 °2Theta.

8. Polymorphic form of clopidogrel (+) -camphor-10-sulfonate according to claims 6 or 7, having an X-ray powder diffractogram as given in Fig. 3.

9. A process for the preparation of the polymorphic form of clopidogrel (-) -camphor-10-sulfonate according to claims 3 to 5 or the polymorphic form of clopidogrel (+) -camphor-10-sulfonate according to claims 6 to 8, wherein a clopidogrel base is dissolved in an organic solvent and a solution or solid form of

(-) -camphor-10-sulfonic acid or (+) -camphor-10-sulfonic acid is added .

10. Process according to claim 9, wherein the solvent is selected from the group of ketones, ester, alcohols and ethers.

11. Process according to claim 9 or 10 wherein the solvent is acetone or ethylacetate .

12. A form of clopidogrel hydrogen sulfate, having characteristic absorption peaks in the FT-IR-spectrum at 590, 721, 761, 884, 1043, 1079, 1189, 1223, 1321, 1436, 1479, 1652, 1750, 2560 and 2924 cm ^x.

13. A form of clopidogrel hydrogen sulfate accordrng to clarm 12, characterized by the FT-IR spectrum represented in Fig. 9.

14. Use of clopidogrel hydrogen sulfate according to claims 12 or 13 for the preparation of the polymorphic form I of clopidogrel hydrogen sulfonate.

15. Process for the preparation of polymorphic form I of clopidogrel hydrogen sulfate, wherein the form of clopidogrel hydrogen sulfate according to claim 12 or 13 is used.

16. Process for the preparation of the form of clopidogrel hydrogen sulfate according to claims 12 and 13 comprising: i) dissolving clopidogrel hydrogen sulfate m a polar protic solvent, ii) adding a less polar aprotic solvent, in) evaporating the solution to dryness under reduced pressure at a temperature from 30 to 60 ⁰C, preferably from 40 to 50 ⁰C.

17. Polymorphic form of cloprdogrel hydrochloride, having characteristic peaks in the X-ray powder diffraction pattern at 9.5, 10.3, 14.3, 15.8, 18.6 °2Theta.

18. Crystalline clopidogrel hydrogen sulfate of polymorphic form I, characterized by a mean particle size larger than 20 μm, preferably larger than 50 μm, most preferably larger than 70 μm.

19. A process for the preparation of clopidogrel hydrogen sulfate of polymorphic form I according to claim 18, comprising: i) adding a sulfuric acid solution in an organic solvent at T2 to a solution of clopidogrel in an organrc solvent at Tl, ii) stirring the suspension after completed addition at T3 for a certain time, in) heating the suspension to T4 under control with a certain heating speed and stirrrng at this temperature for a certain time, iv) isolating the precipitated product, wherein Tl to T3 are temperatures which can be the same or different and are selected from -20 to 40°C, and T4 is a temperature from 0 to 40⁰C.

20. Process according to claim 19, wherein the organic solvent is a C₄ to Ci5 ketone, preferably methyl isobutyl ketone.

21. Process according to claims 19 or 20, wherein the solution of clopidogrel contains methyl isobutyl ketone and methylene chloride .

22. Crystalline polymorphic form I of clopidogrel hydrogen sulfate, characterized by a bulk volume of less than 3 mL/g.

23. A process for the preparation of clopidogrel hydrogen sulfate of form I according to claim 22, comprising: i) suspending clopidogrel hydrogen sulfate m an organic solvent containing dissolved sulfuric acid at a temperature Tl, ii) stirring the suspension for a certain time at a temperature T2, in) heating the suspension to T3 under control with a certain heating speed and stirring at this temperature for a certain time, iv) isolating the precipitated product, wherein

Tl and T2 are temperatures which can be the same or different and are selected from -20 to 40°C, and T3 is a temperature from 0 to 40 °C.

24. Process according to claim 23, wherein the organic solvent is a C₃ to C₈ ester or a C₄ to Ci₅ ketone, preferably ethyl acetate or methyl isobutyl ketone.

25. Pharmaceutical formulation containing a polymorphic form of clopidogrel camphor-10-sulfonate according to any one of claims 3 to 8.

26. Pharmaceutical formulation containing a polymorphic form of clopidogrel hydrogen sulfate according to any one of claims 18 or 22.

27. Pharmaceutical formulation containing a polymorphic form of clopidogrel hydrochloride according to claim 17.